JPY 4,729.00
-129.00 (-2.66%)
JPY · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where 4523.T is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
Of the 500 shown: 446 interventional · 52 observational · 2 expanded access · 227 with posted results
Held by 0 tracked-famous managers · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Post Authorization Registry Study of Participants Treated With LEQEMBINCT07762092observationalIncidence and Severity of Known AEs | — | Not yet recruiting | Other: No Intervention | Alzheimers Disease | 400 | 2036-04-01 | in 3,513 d | 2026-08-13 |
| A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After ChemotherapyNCT06793709observationalNumber of Participants With Adverse Drug Reactions | — | Recruiting | Other: No Intervention | Biliary Tract Cancer | 60 | 2032-11-20 | in 2,285 d | 2026-02-27 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesNCT04300556Dose Escalation Part: Recommended Phase 2 Dose (RP2D) of Farletuzumab EcteribulinRandomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Farletuzumab ecteribulin, Prednisone, Prednisolone, Dexamethasone, Lenvatinib | Solid Tumor | 182 | 2030-08-08 | in 1,450 d | 2026-06-04 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD)NCT07768592Part A (Core Trial): Change from Baseline in [11C]MK-6884 Positron Emission Tomography (PET) Using Non-Displaceable Binding Potential (BPND) at 14 DaysRandomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: E2511, Donepezil | Alzheimers Disease | 32 | 2030-05-06 | in 1,356 d | 2026-08-17 |
| A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseaseNCT03887455Core Study: Change from Baseline in the CDR-SB at 18 MonthsRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Lecanemab IV, Placebo, Lecanemab SC | Early Alzheimer's Disease | 1,906 | 2029-06-30 | in 1,046 d | 2026-04-07 |
| AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate AmyloidNCT04468659A45 Trial: Change From Baseline in Preclinical Alzheimer Cognitive Composite 5 (PACC5) Score at Week 216Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Lecanemab, Placebo | Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease | 1,400 | 2028-12-21 | in 855 d | 2026-06-04 |
| A Study of E6742 in Participants With Systemic Lupus ErythematosusNCT07515014Percentage of Participants who Achieve a BICLA Response with Low Dose of OCS (Prednisone or Equivalent) at Week 24Randomized · Double-masked · Treatment | Phase 2 | Recruiting | Drug: E6742 · Other: Placebo | Systemic Lupus Erythematosus | 256 | 2028-08-05 | in 717 d | 2026-07-02 |
| A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic SeizuresNCT06657378observationalNumber of Participants with Adverse Drug Reactions (ADRs) and Adverse Events (AEs) | — | Recruiting | Other: No Intervention | Partial-Onset Seizures, Primary Generalized Tonic-clonic Seizures | 110 | 2028-06-15 | in 666 d | 2026-07-01 |
| A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in JapanNCT05228158observationalNumber of Participants With Adverse Drug Reactions (ADRs) | — | Active, not recruiting | Drug: Tazemetostat | Lymphoma, Follicular | 145 | 2028-03-31 | in 590 d | 2026-01-02 |
| A Community-Based Screening Program to Identify Participants at High Risk for Amyloid PathologyNCT06043700observationalNumber of Participants With Low, Medium, and High Amyloid Pathology | — | Active, not recruiting | Other: No Intervention | Alzheimer's Disease | 2,000 | 2028-03-31 | in 590 d | 2026-03-05 |
| A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With LecanemabNCT06322667observationalNumber of Participants With Amyloid Related Imaging Abnormality-Oedema/Effusion (ARIA-E) and Amyloid Related Imaging Abnormality-Microhemorrhage and Hemosiderin Deposit, and Cerebellar Microhaemorrhage (ARIA-H) | — | Recruiting | Other: No Intervention | Alzheimer's Disease | 5,000 | 2027-12-31 | in 499 d | 2026-01-23 |
| A Study of Oral E1018 in Healthy Adult ParticipantsNCT06854042Number of Participants With Dose-limiting EventsRandomized · Quadruple-masked · Treatment | Phase 1 | Active, not recruiting | Drug: E1018, Placebo | Malaria, Healthy Participants | 32 | 2027-07-22 | in 337 d | 2026-08-07 |
| A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood EpilepsyNCT04015141Proportion of 50% Responders For All Seizures During the Maintenance Period of Core StudyOpen-label · Treatment | Phase 2 | Active, not recruiting | Drug: Perampanel Oral Suspension, Perampanel Tablet | Pediatric Epileptic Syndrome, Partial-onset Seizures | 100 | 2027-04-06 | in 230 d | 2026-07-10 |
| Study of E7386 in Participants With Selected Advanced NeoplasmsNCT03264664Number of Participants With Dose-limiting Toxicities (DLTs)Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: E7386 | Advanced Neoplasms | 60 | 2027-03-31 | in 224 d | 2026-06-08 |
| A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)NCT03833700Number of Participants with Dose-limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: E7386 | Solid Neoplasms, Colorectal Neoplasms, Gastrointestinal Tumors | 70 | 2027-03-31 | in 224 d | 2026-02-27 |
| A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorNCT04008797Dose Escalation Part: Number of Participants with Dose-limiting Toxicities (DLTs)Randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: E7386, Lenvatinib, Doxorubicin, Paclitaxel | Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms | 301 | 2027-03-31 | in 224 d | 2026-03-24 |
| A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid TumorNCT04078295Phase 1b: Number of Participants with Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: E7389-LF, Nivolumab | Solid Neoplasms | 125 | 2027-03-31 | in 224 d | 2026-02-10 |
| A Study to Evaluate the Efficacy and Safety of E2086 in Adults With NarcolepsyNCT07493265Change from Baseline to Week 4 in MSL for E2086 Compared With Placebo Across Four MWTs in Participants With NT1 and NT2Randomized · Triple-masked · Treatment | Phase 2 | Recruiting | Drug: E2086, Placebo | Narcolepsy | 64 | 2027-02-14 | in 179 d | 2026-05-14 |
| A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's DiseaseNCT07723950observationalPositive Predictive Value (PPV) of algorithms to identify intracerebral hemorrhage >1 cm in diameter | — | Not yet recruiting | Other: No intervention | Alzheimer's Disease | 600 | 2026-12-31 | in 134 d | 2026-07-23 |
| A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's DiseaseNCT06602258Change From Baseline in CSF MTBR-tau-243 at 6 MonthsRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: E2814, Lecanemab, Placebo | Alzheimer's Disease | 105 | 2026-12-03 | in 106 d | 2026-02-11 |
| Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy ParticipantsNCT04271488Cmax: Maximum Observed Plasma Concentration of TasurgratinibNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Tasurgratinib, Tasurgratinib | Hepatic Impairment | 18 | 2026-11-30 | in 103 d | 2026-01-23 |
| A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy ParticipantsNCT07766369Part A, area under concentration versus time curve from zero time (predose) to time of last quantifiable concentration AUC(0-t) of E2086 and its Metabolite M1Non-randomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: E2086 | Healthy Volunteers | 93 | 2026-11-12 | in 85 d | 2026-08-14 |
| A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male ParticipantsNCT07308236Mass Balance Recovery of E2086, Expressed as Cumulative Percent of the Radiolabeled DoseOpen-label · Basic science | Phase 1 | Recruiting | Drug: E2086 | Healthy Volunteers | 10 | 2026-02-23 | — | 2026-03-05 |
| A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control PopulationNCT06744673observationalPercentage of Live Births Reported With MCM in Women of Cohort A Subset and Cohort C | — | Active, not recruiting | Other: No Intervention | Sleep Initiation and Maintenance Disorders, Pregnancy | 861 | 2025-12-30 | — | 2025-06-19 |
| A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast CancerNCT04288089results2024-03-22Maximum Tolerated Dose (MTD) of H3B-6545 and PalbociclibOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Active, not recruiting | Drug: Palbociclib (75, 100, 125 milligram [mg]), H3B-6545 (150, 300, 450 mg) | Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms | 31 | 2022-09-16actual | — | 2026-02-27 |
| Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaNCT02811861results2021-09-24Progression-free Survival (PFS) by Independent Imaging Review (IIR)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Lenvatinib, Everolimus, Pembrolizumab, Sunitinib | Renal Cell Carcinoma | 1,069 | 2020-08-28actual | — | 2026-02-23 |
| Study of E7389 Liposomal Formulation in Participants With Solid TumorNCT03207672Maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: E7389-LF | Solid Tumor | 140 | 2018-07-19actual | — | 2026-03-03 |
| A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast CancerNCT04572295Part 1: Recommended Dose (RD) of E7090 in Combination With Other Anticancer AgentsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E7090, Fulvestrant, Exemestane | Breast Neoplasms | 51 | 2026-06-18actual | — | 2026-07-17 |
| A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast CancerNCT06188559Part 1, Dose Optimization: Number of Participants With Adverse Events (AEs)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: BB-1701 | Breast Cancer | 56 | 2026-03-18actual | — | 2026-05-22 |
| A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene FusionNCT04238715ORROpen-label · Treatment | Phase 2 | Completed | Drug: E7090 | Cholangiocarcinoma | 63 | 2025-11-03actual | — | 2026-03-02 |
| Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerNCT04568902Number of Participants With Dose-limiting Toxicities (DLTs)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: H3B-6545, Antihistamine | Breast Neoplasms | 33 | 2025-10-01actual | — | 2025-10-23 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1NCT06462404Mean Sleep Latency (MSL) as Assessed by the 4 Maintenance of Wakefulness Tests (MWTs) for E2086 Versus Placebo at Day 1Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: E2086, E2086 Placebo, Active Comparator, Active Comparator Placebo | Narcolepsy Type 1 (NT1) | 22 | 2025-03-17actual | — | 2025-06-04 |
| A Study of E7130 in Participants With Solid TumorsNCT03444701Part 1: Number of participants assigned to the every 2 weeks regimen with dose-limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E7130, E7130 | Solid Tumors | 62 | 2024-12-27actual | — | 2025-03-06 |
| A Study of E2086 in Healthy Adult ParticipantsNCT06481488Part A: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: E2086, Placebo | Healthy Volunteers | 32 | 2024-12-13actual | — | 2025-01-16 |
| A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's DiseaseNCT01767311results2026-03-04Core Study Phase: Change From Baseline in Alzheimer's Disease Composite Score (ADCOMS) at Month 12Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg, Placebo, Lecanemab 10 mg/kg | Alzheimer's Disease | 856 | 2024-12-10actual | — | 2026-03-04 |
| A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid TumorsNCT05091346results2025-10-24Phase 1b Part: Number of Participants With Dose-limiting Toxicities (DLTs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: E7386, Pembrolizumab, Lenvatinib | Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms | 89 | 2024-10-15actual | — | 2025-10-24 |
| A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet SyndromeNCT04572243results2025-10-08Core Study: Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days During the Treatment PeriodRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The study was terminated by Sponsor and the decision was not due to any safety or efficacy reasons. | Drug: Placebo, Lorcaserin | Epilepsies, Myoclonic | 22 | 2024-08-15actual | — | 2025-10-08 |
| A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's DiseaseNCT04971733results2025-06-10Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: E2814 | Alzheimer Disease | 8 | 2024-05-24actual | — | 2025-06-10 |
| A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia DisorderNCT05594589results2025-07-03Treatment Period: Change From Baseline in Latency to Persistent Sleep (LPS) on Day 30 of Lemborexant 5 mg Compared to PlaceboRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Lemborexant · Other: PBO | Sleep Initiation and Maintenance Disorders | 65 | 2024-04-26actual | — | 2025-07-03 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy ParticipantsNCT05726851Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Randomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: E2025, Placebo | Healthy Volunteers | 32 | 2024-01-30actual | — | 2024-03-25 |
| A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly ParticipantsNCT05745207Number of Participants With Treatment-emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Other | Phase 1 | Completed | Drug: E2086, Placebo | Healthy Volunteers | 53 | 2024-01-18actual | — | 2024-10-02 |
| Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib TrialsNCT03477175results2025-01-07Number of Participants With Any Treatment-Emergent Serious Adverse Events (TESAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: E7080, Comparator Drug, Comparator Drug: Sorafenib | Solid Tumors | 40 | 2023-12-21actual | — | 2025-01-07 |
| A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular CarcinomaNCT04763408observationalNumber of Participants With Hepatotoxicity Treatment-emergent Adverse Events (TEAEs) With Lenvatinib | — | Completed | Drug: Lenvatinib, Sorafenib | Carcinoma, Hepatocellular | 335 | 2023-12-13actual | — | 2024-07-18 |
| Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast CancerNCT03250676results2025-02-25Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: H3B-6545 | Breast Neoplasms, Breast Cancer, Estrogen-receptor Positive Breast Cancer, Cancer, Breast, Breast Cancer Female, Breast Adenocarcinoma, Estrogen Receptor Positive Tumor, ER Positive | 151 | 2023-10-26actual | — | 2025-02-25 |
| A Study Based on the French National Health Insurance Database in Participants With Psychotic DisordersNCT05633108observationalTime from Discharge from a Psychiatric Hospitalization to the Next Psychiatric Rehospitalization | — | Completed | Other: No Intervention | Psychotic Disorders | 579,728 | 2023-09-30actual | — | 2023-11-18 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus ParticipantsNCT05278663Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Randomized · Double-masked · Treatment | Phase 1/2 | Completed | Drug: E6742 · Other: Placebo | Lupus Erythematosus, Systemic | 26 | 2023-09-04actual | — | 2023-09-29 |
| A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male ParticipantsNCT05607537Part 1, %F: Percent Absolute Oral Bioavailability for (14C)E7386 and E7386Non-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: E7386 Tablet, (14C)E7386 Capsule, (14C)E7386 | Healthy Volunteers | 15 | 2023-08-31actual | — | 2023-09-21 |
| A Study to Assess the Safety and Tolerability of E8001 in Healthy Male ParticipantsNCT04609852Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Randomized · Single-masked · Other | Phase 1 | Completed | Drug: E8001, Placebo | Healthy Volunteers | 36 | 2023-08-18actual | — | 2023-09-25 |
| A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With GoutNCT05007392results2025-07-30Percentage of Participants With Serum Uric Acid (SUA) Level <=6.0 mg/dL at Week 24 (LOCF)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dotinurad, Febuxostat · Other: Dotinurad Matched Placebo, Febuxostat Matched Placebo | Gout | 451 | 2023-06-14actual | — | 2025-07-30 |
| A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult ParticipantsNCT04840927Cmax: Maximum Observed Plasma Concentration for E7386Randomized · Open-label · Other | Phase 1 | Withdrawnsponsor's stated reason: Delay in availability of IMP | Drug: E7386 | Healthy Volunteers | 0 | 2023-05-17actual | — | 2023-11-24 |
| A Study of Lemborexant in Chinese Participants With Insomnia DisorderNCT04549168results2024-12-20Change From Baseline of Mean Latency to Persistent Sleep (LPS) Over the Last 2 Nights of 1 Month of Treatment of Lemborexant 10 mg Compared to PlaceboRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Lemborexant, Placebo | Sleep Initiation and Maintenance Disorders | 194 | 2023-03-17actual | — | 2024-12-20 |
| A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)NCT05137847observationalPercentage of Participants with ADR | — | Completed | Drug: Remitoro | Lymphoma, T-cell, Peripheral, Lymphoma, T-cell, Cutaneous | 118 | 2023-03-17actual | — | 2023-12-12 |
| A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy ParticipantsNCT04231513SAD, Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Randomized · Double-masked · Other | Phase 1 | Completed | Drug: E2814, E2814-matched placebo | Healthy Volunteers | 72 | 2023-03-09actual | — | 2023-04-06 |
| A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized EpilepsyNCT04252846observationalRetention Rate at Month 12 | — | Completed | Drug: Perampanel | Idiopathic Generalized Epilepsy, Partial Onset Seizures, Generalised Tonic-Clonic Seizures | 191 | 2023-01-12actual | — | 2023-02-09 |
| A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy ParticipantsNCT05533801AUC(0-t): Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration for LecanemabRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Lecanemab, Lecanemab | Healthy Volunteers | 160 | 2023-01-06actual | — | 2023-01-18 |
| A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular CarcinomaNCT03418922results2024-06-20Part 1: Number of Participants With Dose-Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Lenvatinib, Nivolumab | Carcinoma, Hepatocellular | 30 | 2022-12-28actual | — | 2024-06-20 |
| A Single and Multiple Dose Study of Dotinurad in Chinese Healthy ParticipantsNCT05278676Single-dose Part, Cmax: Maximum Observed Concentration for DotinuradNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Dotinurad | Healthy Volunteers | 26 | 2022-12-13actual | — | 2023-09-14 |
| Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut SyndromeNCT02175173observationalInvestigations on adverse events and adverse drug reactions | — | Completed | Drug: Rufinamide | Lennox-Gastaut Syndrome | 707 | 2022-11-02actual | — | 2023-02-21 |
| A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid TumorsNCT03386942Part 1: Number of participants with dose-limiting toxicities (DLTs)Open-label · Treatment | Phase 1 | Completed | Drug: Farletuzumab Ecteribulin | Solid Tumors | 82 | 2022-10-26actual | — | 2022-11-28 |
| A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)NCT04724109observationalNumber of Participants with Adverse Events (AEs) and Adverse Drug Reactions (ADRs) | — | Completed | Drug: Equfina | Parkinson Disease | 1,088 | 2022-10-13actual | — | 2022-12-16 |
| Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System TumorsNCT03245151results2023-08-30Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib in Combination With EverolimusNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Lenvatinib, Everolimus | Recurrent and Refractory Solid Tumors | 64 | 2022-09-30actual | — | 2023-08-30 |
| A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102NCT04109092Dose Escalation Part: Number of Participants with Dose-limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: There was no enrolment of participants.Unscheduled Clinical Study Closure - Eisai Network Company Decision, November 12, 2020. | Drug: E7766 | Urinary Bladder Neoplasms | 0 | 2022-09-29 | — | 2020-12-14 |
| Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With EpilepsyNCT02914314results2023-09-15Dose Normalized Area Under the Concentration-Time Curve for Dosing Interval at Steady State (AUCtau,ss) of Perampanel During the Maintenance Period of the Core Phase for Non-EIAED ParticipantsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: perampanel | Epilepsy | 26 | 2022-08-23actual | — | 2024-03-15 |
| A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly ParticipantsNCT05147337Number of Participants With Treatment-emergent Adverse Events (TEAEs)Randomized · Double-masked · Other | Phase 1 | Completed | Drug: E2511, Placebo | Healthy Volunteers | 47 | 2022-08-18actual | — | 2022-09-09 |
| Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101NCT04144140results2024-03-07Dose Escalation Part: Number of Participants With Dose-limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: The study was terminated earlier due to a business decision; which was unrelated to safety. In addition, there was no clinical activity data that informed the decision. | Drug: E7766 | Lymphoma, Advanced Solid Tumors | 24 | 2022-07-26actual | — | 2024-03-07 |
| A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory OsteosarcomaNCT04154189results2023-08-07Progression-free Survival (PFS) by Independent Imaging Review (IIR) AssessmentRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Lenvatinib, Ifosfamide, Etoposide, Lenvatinib | Osteosarcoma | 81 | 2022-06-22actual | — | 2024-07-22 |
| A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia.NCT04573556observationalNumber of Participants with Adverse Events (AEs) and Adverse Drug Reactions (ADRs) | — | Completed | Drug: Lemborexant | Sleep Initiation and Maintenance Disorders | 550 | 2022-03-17actual | — | 2022-04-05 |
| Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])NCT03517449results2021-11-17Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) ParticipantsRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin | Endometrial Neoplasms | 827 | 2022-03-01actual | — | 2026-03-19 |
| A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT04647383results2023-10-10OSA Cohort: Apnea-Hypopnea Index (AHI) on Day 8 of Treatment Periods 1 and 2Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Placebo, Lemborexant 10 mg, Placebo, Lemborexant 10 mg | Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive, Respiration Disorders | 63 | 2022-02-10actual | — | 2023-10-10 |
| A Study of Overall Survival in Participants With Unresectable Hepatocellular CarcinomaNCT04008082observationalOverall Survival (OS) | — | Completed | Drug: Lenvatinib | Carcinoma, Hepatocellular, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms | 412 | 2022-01-28actual | — | 2022-03-08 |
| Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene MutationNCT03456726results2022-12-16Objective Response Rate (ORR) Based on Independent Reviewer AssessmentNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Tazemetostat | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | 20 | 2021-12-17actual | — | 2022-12-16 |
| A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid CopathologyNCT04764669results2022-09-26Percent Change From Baseline in Cerebrospinal Fluid (CSF) Cyclic Guanosine Monophosphate (cGMP) at Week 9Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: E2027 | Lewy Body Disease, Parkinson Disease | 34 | 2021-12-08actual | — | 2022-09-26 |
| A Study of Subcutaneous Lecanemab in Healthy ParticipantsNCT05045716AUC(0-t): Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration for LecanemabRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Lecanemab, Lecanemab | Healthy Volunteers | 60 | 2021-12-07actual | — | 2022-01-19 |
| A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell LymphomaNCT01871727results2024-11-13Lead-In Part: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: E7777 9 mcg/kg | Persistent or Recurrent Cutaneous T-Cell Lymphoma | 112 | 2021-12-06actual | — | 2024-11-13 |
| A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced DiseaseNCT02915783results2020-07-13Objective Response Rate (ORR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: lenvatinib, everolimus | Non Clear Cell Renal Cell Carcinoma (nccRCC) | 41 | 2021-11-02actual | — | 2023-01-17 |
| Phase 1 Study of E7090 in Subjects With Solid TumorNCT02275910results2025-12-16Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: E7090 | Tumors | 40 | 2021-09-03actual | — | 2025-12-16 |
| A Study to Evaluate Lemborexant in Milk of Healthy Lactating WomenNCT04890561Ae: Cumulative Total (Unchanged) Amount of Lemborexant Excreted in Breast Milk Over the Entire CollectionOpen-label · Treatment | Phase 1 | Completed | Drug: Lemborexant | Healthy Volunteers | 8 | 2021-08-12actual | — | 2021-09-05 |
| A Study to Assess the Safety and Tolerability of E2730 After Multiple Dose and the Food Effect After Single Dose in Healthy ParticipantsNCT04676685Number of Participants With Treatment-emergent Adverse Events (TEAEs)Randomized · Triple-masked · Other | Phase 1 | Completed | Drug: E2730, E2730-matched placebo | Healthy Volunteers | 32 | 2021-06-23actual | — | 2021-08-26 |
| A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult ParticipantsNCT04683185Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Randomized · Double-masked · Other | Phase 1 | Completed | Drug: E6742, Placebo | Healthy Volunteers | 24 | 2021-06-21actual | — | 2021-07-20 |
| Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut SyndromeNCT02834793results2022-03-09Core Study Phase: Median Percent Change in Drop Seizure Frequency Per 28 Days During Double-blind Treatment Relative to the Prerandomization Phase (Baseline)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Sponsor's decision | Drug: Placebo, Perampanel | Lennox-Gastaut Syndrome (LGS) | 101 | 2021-05-26actual | — | 2022-03-09 |
| A Study to Assess the Safety and Tolerability of E2511 in Healthy ParticipantsNCT04547361Cohorts 1, 2, 3, 4, 5, 6, 7: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Randomized · Double-masked · Other | Phase 1 | Completed | Drug: E2511, E2511 Matched Placebo | Healthy Volunteers | 45 | 2021-05-26actual | — | 2021-07-12 |
| Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid TumorsNCT03245450results2022-06-28Phase 1: Recommended Phase 2 Dose (RP2D) of Eribulin Mesilate in Combination With Irinotecan HydrochlorideOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Eribulin mesilate, Irinotecan hydrochloride | Refractory or Recurrent Solid Tumors, Rhabdomyosarcoma, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma | 40 | 2021-05-17actual | — | 2022-06-28 |
| Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic SeizuresNCT03288129results2022-05-16Percentage of Participants Remaining on Perampanel Treatment at 3 Months After the Initiation of TreatmentOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Perampanel | Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures | 54 | 2021-04-27actual | — | 2022-05-16 |
| A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy ParticipantsNCT04565574Cmax: Maximum Observed Plasma Concentration of E7090Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E7090, Rabeprazole 20 mg, Rifampin 600 mg | Healthy Participants | 42 | 2021-03-31actual | — | 2021-11-01 |
| Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic SeizuresNCT03059381observationalNumber of participants with any serious adverse event | — | Completed | Drug: Fycompa | Partial Seizures (With or Without Secondary Generalized Seizures), Primary Generalized Tonic-clonic Seizures | 519 | 2021-03-21actual | — | 2022-08-05 |
| A Single and Multiple Dose Study of Lemborexant in Healthy Chinese ParticipantsNCT04555733Cmax: Maximum Observed Plasma Concentration for Lemborexant and Its Metabolites (M4, M9, and M10) Following Single Dose in All CohortsNon-randomized · Open-label · Other | Phase 1 | Completed | Drug: Lemborexant | Healthy Volunteer | 26 | 2021-01-13actual | — | 2021-07-19 |
| Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)NCT03441360results2022-01-28Percentage of Participants With Objective ResponseNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Eribulin mesylate | Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma | 23 | 2021-01-07actual | — | 2022-10-05 |
| A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male ParticipantsNCT04493255feu: Percentage of Administered Radioactive Dose of [14C]E7090 Excreted in UrineOpen-label · Other | Phase 1 | Completed | Drug: [14C]E7090 | Healthy Volunteers | 8 | 2020-10-21actual | — | 2021-02-04 |
| A Study to Determine the Signs and Symptoms That Impact Daily Life of Participants With Irregular Sleep-Wake Rhythm DisorderNCT04300569observationalDevelopment of Scale for the Assessment of the Signs and Symptoms of Irregular Sleep-wake Rhythm Disorder (ISWRD) Based on Interview Data | — | Completed | Other: Non-interventional | Irregular Sleep Wake Rhythm Disorder | 37 | 2020-09-07actual | — | 2020-10-27 |
| A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid TumorsNCT02501096results2023-07-20Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of LenvatinibOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Lenvatinib, Pembrolizumab | Tumors | 357 | 2020-08-18actual | — | 2023-07-20 |
| Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid TumorsNCT03006887results2021-05-20Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: lenvatinib, pembrolizumab | Solid Tumors | 6 | 2020-04-15actual | — | 2021-05-20 |
| Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy BodiesNCT03467152results2022-08-01Change From Baseline in the Montreal Cognitive Assessment (MoCA) Total Score at Week 12 of TreatmentRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Irsenontrine, Placebo | Dementia With Lewy Bodies | 326 | 2020-04-15actual | — | 2022-08-01 |
| Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 YearsNCT03338296results2021-07-19Change in Body Mass Index (BMI) From Baseline up to Week 52Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Terminatedsponsor's stated reason: Study was terminated as Eisai agreed to voluntarily withdraw Belviq XR from US market. | Drug: lorcaserin hydrochloride XR, Placebo | Obesity | 278 | 2020-04-03actual | — | 2021-07-19 |
| A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of InsomniaNCT04009577results2021-04-12Percentage of Overall Participants Who Transitioned to LEM at the End of the Titration Period of Core StudyRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: LEM 5 mg, LEM 10 mg | Insomnia | 53 | 2020-03-17actual | — | 2021-04-12 |
| Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male SubjectsNCT03402178Part A: Mean value of the maximum observed concentration (Cmax) of E2082 under a fasted state for the single ascending dose (SAD) Cohorts 1-10Randomized · Double-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Safety Review | Drug: E2082, Placebo | Healthy Participants | 118 | 2020-02-20actual | — | 2021-06-30 |
| A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular CarcinomaNCT03663114observationalNumber of Participants With Hepatic Encephalopathy Risk Factors | — | Completed | Drug: Lenvatinib | Carcinoma, Hepatocellular | 713 | 2020-02-20actual | — | 2021-01-22 |
| Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell CarcinomaNCT03173560results2021-03-05Objective Response Rate at Week 24 (ORR24W)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: lenvatinib, everolimus | Renal Cell Carcinoma | 343 | 2020-02-14actual | — | 2025-04-01 |
| Clinical Trial of Ultra-high Dose Methylcobalamin for ALSNCT03548311Treatment Phase: ALSFRS-RRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: methylcobalamin, saline solution | Amyotrophic Lateral Sclerosis | 130 | 2020-02-14actual | — | 2025-03-26 |
| A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's DiseaseNCT02956486results2021-02-03Core Phase: Change From Baseline up to Month 24 in the Clinical Dementia Rating-sum of Boxes (CDR-SB) ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Due to an unfavorable risk-benefit ratio including no evidence of potential efficacy, and the adverse event profile of E2609 being worse than placebo. | Drug: Elenbecestat, Placebo | Alzheimer's Disease | 2,212 | 2020-01-15actual | — | 2021-02-03 |
| Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's DiseaseNCT02322021results2021-03-05Core Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: This study was terminated early by the sponsor on the recommendation of an independent data safety monitoring board following review of unblinded data from the Phase 3 studies E2609-G000-301 (NCT02956486) and E2609-G000-302 (NCT03036280). | Drug: E2609, Placebo | Alzheimer Disease, Dementia, Alzheimer Type | 70 | 2019-12-20actual | — | 2021-03-05 |
| A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety ProfileNCT02702388results2021-01-11Objective Response Rate (ORR) as of Week 24 (ORR24wk)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Lenvatinib, Lenvatinib matching placebo | Thyroid Cancer | 241 | 2019-12-12actual | — | 2021-11-24 |
| A Study of Intravenous Perampanel in Japanese Participants With EpilepsyNCT03754582results2021-01-05Number of Participants With Serious Adverse Events (SAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Perampanel, Perampanel | Epilepsy, Seizures | 21 | 2019-12-10actual | — | 2021-01-05 |
| A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular CarcinomaNCT03006926results2020-12-31DLT Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: lenvatinib, pembrolizumab (200 mg) | Hepatocellular Carcinoma | 104 | 2019-10-31actual | — | 2023-12-13 |
| A Food-Effect Study of E7386 in Healthy ParticipantsNCT03996226Cmax: Maximum Observed Plasma Concentration for E7386Randomized · Open-label · Other | Phase 1 | Completed | Drug: E7386 | Food Effect in Healthy Participants | 17 | 2019-10-29actual | — | 2019-11-14 |
| A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male ParticipantsNCT04023877Cumulative Percent of the Radiolabeled Dose of [14C]E2027 in Biological Matrices (Blood, Urine, Feces and Toilet Tissue)Open-label · Treatment | Phase 1 | Completed | Drug: E2027 | Dementias With Lewy Bodies | 8 | 2019-10-11actual | — | 2019-12-03 |
| Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic SeizuresNCT03059329observationalNumber of participants with any serious adverse event | — | Completed | Drug: Fycompa | Partial Seizures (With or Without Secondary Generalized Seizures), Primary Generalized Tonic-clonic Seizures | 3,809 | 2019-09-13actual | — | 2022-03-02 |
| Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)NCT02753595results2020-07-13Phase 1b: Recommended Phase 2 Dose (RP2D) of Eribulin Mesylate in Combination With PEGPH20Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: evolving standard of care and difficulties of enrolling participants | Drug: Eribulin mesylate, Eribulin mesylate, Eribulin mesylate · Other: Biologic: PEGylated recombinant human hyaluronidase (PEGPH20), Biologic: PEGylated recombinant human hyaluronidase | Metastatic Breast Cancer | 25 | 2019-08-16actual | — | 2020-07-13 |
| Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)NCT02513472results2020-08-14Objective Response Rate (ORR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Eribulin Mesylate, Pembrolizumab | Breast Neoplasm | 258 | 2019-07-31actual | — | 2022-05-05 |
| A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in ChinaNCT02966093Progression-free survival (PFS)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Lenvatinib, Placebo | Differentiated Thyroid Cancer (DTC) | 151 | 2019-07-31actual | — | 2022-01-26 |
| Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With OsteosarcomaNCT02432274results2020-09-17Cohort 1: Recommended Dose (RD) of LenvatinibNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Lenvatinib, Lenvatinib, Lenvatinib, Lenvatinib, Lenvatinib, Ifosfamide, Etoposide, Ifosfamide, Etoposide | Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC) | 117 | 2019-07-18actual | — | 2023-07-11 |
| Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical DystoniaNCT02175693observationalOverall assessments of the improvement in the seriousness of seizures | — | Completed | — | Cervical Dystonia | 1,647 | 2019-06-30actual | — | 2020-01-09 |
| A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast CancerNCT03583944Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Open-label · Treatment | Phase 4 | Completed | Drug: Eribulin Mesylate | Breast Neoplasms | 200 | 2019-06-28actual | — | 2019-11-27 |
| A Pharmacokinetic (PK) Study of Three Types of E0302 Sustained Release (SR) Tablets Compared With E0302 Immediate Release (IR) Tablet Under Fed Conditions in Healthy ParticipantsNCT03885882Cmax: Maximum Observed Plasma Concentration for E0302 SR1, SR2, SR3 and IRRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: E0302 SR1, E0302 SR3, E0302 SR2, E0302 IR | Healthy Subjects | 24 | 2019-06-26actual | — | 2019-12-24 |
| A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive EpilepsyNCT03686033results2020-09-28Mean Change From Baseline in the Photoparoxysmal Response (PPR) Range in the Most Sensitive Eye Condition at 8 Hours Postdose on Day 1 of Each Treatment PeriodRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Safety Review | Drug: Placebo, E2082 | Photosensitive Epilepsy | 8 | 2019-06-18actual | — | 2020-09-28 |
| A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian CancerNCT02289950results2021-09-02Progression Free Survival (PFS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Farletuzumab, Placebo | Platinum-Sensitive Ovarian Cancer in First Relapse | 332 | 2019-05-31actual | — | 2021-09-02 |
| A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal SeizuresNCT04257604observationalPercentage Change From Baseline in all Seizures Frequency at Month 6 | — | Completed | Drug: Perampanel | Partial Seizures | 243 | 2019-04-30actual | — | 2020-02-06 |
| Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell LymphomaNCT02676778results2021-07-15Objective Response Rate (ORR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: E7777 | Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma | 45 | 2019-04-26actual | — | 2021-07-15 |
| Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With EpilepsyNCT03208660observationalPercentage of participants remaining on Fycompa treatment at specified time points after initiation of treatment (Retention rate) | — | Completed | Drug: Fycompa | Epilepsy | 2,000 | 2019-03-15actual | — | 2019-04-11 |
| Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)NCT03201900results2020-02-25Percentage of Participants With Partial-onset Seizures (POS) Who Achieved Seizure-free Status During the 26-week Maintenance Period of 4 mg PerampanelOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: E2007 | Partial Onset Seizures | 91 | 2019-02-28actual | — | 2021-08-05 |
| A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive EpilepsyNCT03603639results2022-05-04Mean Change From Baseline in the Standard Photosensitivity Response (SPR) in the Most Sensitive Eye Condition at 8 Hours Post-dose on Day 1 of Each Treatment PeriodRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was stopped due to efficacy reasons. | Drug: Placebo, E2730 | Photosensitive Epilepsy | 6 | 2019-02-14actual | — | 2022-05-04 |
| Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic SeizuresNCT02849626results2020-04-06Percentage of Participants With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs) for Total Group of Participants - Core Phase and Extension Phase A of This StudyOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Perampanel | Partial-Onset or Primary Generalized Tonic-Clonic Seizures | 180 | 2019-02-05actual | — | 2022-10-28 |
| Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)NCT02952820results2020-01-21Change From Baseline in Subjective Sleep Onset Latency (sSOL) at Month 6Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: lemborexant, Placebo | Insomnia Disorder | 971 | 2019-01-08actual | — | 2020-02-06 |
| Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)NCT03433703results2019-12-06Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study recruitment was stopped due to difficulty in enrolling the targeted number of participants. | Drug: Lenvatinib | Carcinoma, Hepatocellular | 8 | 2019-01-07actual | — | 2019-12-06 |
| Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid TumorNCT03009292Area under the concentration-time curve over the dosing interval on multiple dosing (AUC[0-τ])Open-label · Treatment | Phase 1 | Completed | Drug: lenvatinib | Solid Tumor | 12 | 2018-12-24actual | — | 2021-09-28 |
| A Study on Safety and Efficacy in Patients With Soft Tissue SarcomasNCT03058406observationalNumber of Adverse Events (AEs) and Adverse Drug Reactions (ADRs) | — | Completed | Drug: Eribulin mesylate | Sarcoma, Soft Tissue | 256 | 2018-11-04actual | — | 2020-04-06 |
| A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)NCT02657369results2019-10-15Objective Response Rate (ORR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Overall response rate was 3% (only 1 out of 33 participants had confirmed PR). | Drug: Lenvatinib 24 mg | Thyroid Carcinoma, Anaplastic | 34 | 2018-09-26actual | — | 2019-10-15 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy ParticipantsNCT03451890Mean maximum observed concentration (Cmax) for E2730 and the N-acetyl metabolite (M1) in plasmaRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: E2730, Placebo | Healthy Participants | 32 | 2018-09-26actual | — | 2019-03-04 |
| Study of Lemborexant-Alcohol Interaction in Healthy SubjectsNCT03483636Change from baseline in body sway, as assessed by an ataxia meter measuring directional trunk movements, for lemborexant plus alcohol compared to lemborexant aloneRandomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: Lemborexant, Alcohol, Placebo | Healthy Subjects | 24 | 2018-09-12actual | — | 2018-10-17 |
| A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy ParticipantsNCT03627936Maximum Observed Plasma Concentration (Cmax) of LorcaserinRandomized · Open-label · Other | Phase 1 | Completed | Drug: Lorcaserin manufactured at Zofingen, Lorcaserin manufactured at Kawashima | Healthy Participants | 40 | 2018-09-02actual | — | 2018-10-17 |
| Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal ImpairmentNCT03443063results2020-01-18Maximum Observed Plasma Concentration (Cmax) of LemborexantNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Lemborexant | Renal Impairment | 16 | 2018-08-24actual | — | 2020-03-12 |
| Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep ApneaNCT03471871results2020-01-18HV Cohort: Peripheral Oxygen Saturation (SpO2) During Total Sleep Time (TST) on Day 1 of TreatmentRandomized · Double-masked · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Placebo, Lemborexant 10 mg, Lemborexant 25 mg, Placebo, Lemborexant 10 mg | Obstructive Sleep Apnea, Healthy Subjects | 146 | 2018-08-03actual | — | 2020-02-17 |
| Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease DementiaNCT03001557results2020-01-14Core Phase: Change From Baseline in Mean Actigraphy Sleep Efficiency (aSE) With Lemborexant Compared to Placebo During Week 1 of TreatmentRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Core Phase ↗ · Statistical Analysis Plan: Extension Phase ↗ | Phase 2 | Completed | Drug: Lemborexant 2.5 mg, Lemborexant 5 mg, Lemborexant 10 mg, Lemborexant 15 mg, Lemborexant-matched placebo | Irregular Sleep-Wake Rhythm Disorder | 63 | 2018-07-26actual | — | 2021-05-17 |
| A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular DiseaseNCT02660983results2019-10-04Double Blind (DB) Phase: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) Score (LOCF) at Week 24Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Donepezil hydrochloride, Donepezil matching placebo, Donepezil hydrochloride | Dementia Associated With Cerebrovascular Disease | 302 | 2018-07-13actual | — | 2020-01-10 |
| A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative UsersNCT03158025Mean peak Maximum Effect (Emax) score for Drug Liking on a Visual Analog Scale (VAS)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Zolpidem tablets, Suvorexant tablets, over-encapsulated, Lemborexant tablets, Placebo lemborexant, Placebo zolpidem, Placebo suvorexant | Insomnia Disorders | 39 | 2018-07-04actual | — | 2020-06-29 |
| Pharmacokinetic Study of Perampanel in Chinese Healthy SubjectsNCT03424564Single-dose Part: Mean value of the maximum observed concentration (Cmax) postdose of perampanelNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Perampanel | Healthy Subjects | 44 | 2018-05-25actual | — | 2018-08-28 |
| A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to BiologicsNCT02960490results2021-08-23Core Treatment Phase: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 12 Based on Non-responder Imputation (NRI)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Core and Entire Treatment Phase ↗ · Statistical Analysis Plan: Extension Phase ↗ | Phase 2 | Completed | Drug: E6011, Placebo | Rheumatoid Arthritis | 66 | 2018-05-16actual | — | 2021-08-23 |
| A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk FactorsNCT02019264results2019-07-16Time From Randomization to First Occurrence of Major Adverse Cardiovascular Events (MACE) at Interim AnalysisRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Lorcaserin hydrochloride, Placebo | Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes | 14,673 | 2018-05-14actual | — | 2019-07-16 |
| Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy SubjectsNCT03440424results2020-01-18Cmax: Maximum Plasma Concentration of LemborexantNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Lemborexant | Hepatic Impairment | 24 | 2018-04-23actual | — | 2020-03-20 |
| Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy SubjectsNCT03451110Part 1 (Lemborexant plus Loestrin): Mean maximum observed concentration (Cmax) of lemborexant and metabolitesNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: lemborexant, Loestrin, famotidine, fluconazole | Healthy Subjects | 50 | 2018-03-23actual | — | 2018-09-06 |
| Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese SubjectsNCT03399734Maximum observed concentration (Cmax)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Perampanel, Perampanel | Healthy Participants | 24 | 2018-03-09actual | — | 2018-10-29 |
| A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to MethotrexateNCT02960438results2021-06-21Treatment Phase: Percentage of Participants Who Achieved an American College of Rheumatology 20 (ACR20) Response at Week 12 Based on Non-responder Imputation (NRI)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Treatment Phase ↗ · Statistical Analysis Plan: Extension Phase ↗ | Phase 2 | Completed | Drug: E6011, Placebo | Rheumatoid Arthritis | 273 | 2018-02-28actual | — | 2021-06-21 |
| Study of E7046 in Subjects With Selected Advanced MalignanciesNCT02540291results2020-02-17Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Terminated due to, licensing agreement granting exclusive rights of research, development, manufacture and marketing of Eisai's E7046 to Adlai Nortye Biopharma. | Drug: E7046 | Tumors | 31 | 2018-02-27actual | — | 2020-02-17 |
| Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy SubjectsNCT03376997Mean maximum observed concentration (Cmax) postdose of perampanelRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Perampanel, Perampanel | Healthy Participants | 48 | 2018-02-16actual | — | 2018-09-07 |
| A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 YearsNCT02033902observationalNumber of Treatment Emergent Adverse Events (TEAEs) of interest | — | Completed | Drug: Perampanel | Epilepsy | 500 | 2018-01-31actual | — | 2018-09-07 |
| Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)NCT02783729results2020-02-11Change From Baseline in Mean Latency to Persistent Sleep (LPS) of Lemborexant 10 mg and Lemborexant 5 mg Compared to Placebo on Days 29/30Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Lemborexant, Lemborexant, Lemborexant-matched placebo, Zolpidem tartrate, Zolpidem-matched placebo | Insomnia | 1,006 | 2018-01-30actual | — | 2024-11-12 |
| A Study to Evaluate the Food-Effect of H3B-6527NCT03424577Mean area under the plasma-concentration time curve from time 0 through the last measurable concentration (AUC0-t) of H3B-6527Open-label · Basic science | Phase 1 | Completed | Drug: H3B-6527 | Healthy Participants | 17 | 2018-01-27actual | — | 2018-02-07 |
| Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.NCT02371174observationalNumber of participants with adverse events and serious adverse events | — | Completed | — | Breast Cancer, HER2-negative Breast Cancer | 651 | 2018-01-21actual | — | 2018-07-13 |
| Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and OlderNCT03008447Change from time-matched baseline in postural stability for LEM5 and LEM10 compared to zolpidem (ZOL) at approximately 4 hours postdoseRandomized · Triple-masked · Other | Phase 1 | Completed | Drug: LEM5, LEM10, ZOL, PBO | Healthy Subjects | 60 | 2018-01-03actual | — | 2019-08-01 |
| Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition in Patients With Change From Botulinum Toxin Type ANCT02175719observationalWhole improvement level | — | Completed | — | Cervical Dystonia | 150 | 2017-12-31actual | — | 2018-07-11 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy SubjectsNCT02873156Maximum drug concentration (Cmax)Randomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: E2027, E2027 matched placebo | Healthy Subjects | 74 | 2017-11-29actual | — | 2018-09-07 |
| Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose AspirinNCT02423187observationalIncidence of adverse drug reactions | — | Completed | Other: No Intervention | Gastric Ulcer, Duodenal Ulcer | 1,568 | 2017-10-30actual | — | 2018-08-28 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult SubjectsNCT03082235Number of participants with any serious adverse event and number of participants with any non-serious adverse eventRandomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: E6742, Placebo | Healthy Participants | 72 | 2017-10-11actual | — | 2018-09-07 |
| Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and TaxanesNCT02225470Progression-Free Survival (PFS) of Eribulin Arm by tumor assessment : Time to disease progressionRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: E7389 (Eribulin Mesylate), Vinorelbine injection | HER2-Negative Breast Cancer, Triple Negative Breast Cancer, Breast Cancer, Cancer of Breast, Breast Tumors | 530 | 2017-09-29actual | — | 2018-08-28 |
| A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaNCT03009344results2022-11-10Number of Participants With Dose-limiting Toxicities (DLTs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Tazemetostat | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | 7 | 2017-07-12actual | — | 2022-11-10 |
| Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein BindingNCT02998775Number of participants with any serious adverse event and any non-serious adverse eventNon-randomized · Open-label · Basic science | Early Phase 1 | Completed | Drug: Plasma Sampling | Hepatic Impairment; Renal Impairment | 54 | 2017-07-08actual | — | 2018-09-07 |
| A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With EpilepsyNCT04230044observationalNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) | — | Completed | Drug: Perampanel | Epilepsy, Partial-onset Seizures | 117 | 2017-07-03actual | — | 2020-01-18 |
| Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)NCT02953743Mean maximum observed concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Lenvatinib | Unresectable Hepatocellular Carcinoma (HCC) | 25 | 2017-06-28actual | — | 2021-04-01 |
| Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)NCT02454478results2019-02-08Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Lenvatinib, Everolimus | Carcinoma, Renal Cell | 7 | 2017-05-29actual | — | 2019-03-19 |
| A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)NCT02345213Clinician's Interview-Based Impression of Change, Plus Caregiver Input Version (CIBIC-plus)Randomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: E2020, Placebo | Dementia, Lewy Body, Lewy Body Disease | 160 | 2017-05-15actual | — | 2019-01-08 |
| A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT00445172Number of participants with Adverse Events as a Measure of safetyOpen-label · Treatment | Phase 2/3 | Completed | Drug: E0302 (mecobalamin) | Amyotrophic Lateral Sclerosis (ALS) | 135 | 2017-03-31actual | — | 2023-06-18 |
| Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).NCT02448784observationalMean Mini-Mental State Examination (MMSE) score | — | Completed | Drug: Donepezil Hydrochloride | Dementia With Lewy Body Disease | 591 | 2017-03-30actual | — | 2018-07-11 |
| Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese SubjectsNCT03055962Number of participants with any serious adverse event and number of participants with any non-serious adverse eventRandomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: E2609, Placebo | Healthy Participants | 16 | 2017-03-29actual | — | 2017-04-18 |
| Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730NCT03054194Number of participants with any serious adverse event and number of participants with any non-serious adverse eventRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: E2730, Placebo | Healthy Participants | 8 | 2017-03-02actual | — | 2018-09-07 |
| Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly SubjectsNCT02583451Change of standard deviation of lateral position (SDLP) during an on-road driving testRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: Placebo tablet matching lemborexant, Placebo tablet matching zopiclone, Zopiclone 7.5 mg, Lemborexant 2.5 mg, Lemborexant 5 mg, Lemborexant 10 mg | Healthy Participants | 48 | 2017-01-31actual | — | 2018-09-06 |
| Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective ProcedureNCT01976104results2018-02-27Percentage of Participants Who Did Not Require a Platelet Transfusion After Randomization and up to 7 Days Following a Scheduled ProcedureRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: avatrombopag (lower baseline platelet count), placebo (lower baseline platelet count), avatrombopag (higher baseline platelet count), placebo (higher baseline platelet count) | Thrombocytopenia Associated With Liver Disease | 204 | 2017-01-30actual | — | 2018-02-27 |
| Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective ProcedureNCT01972529results2018-02-27Percentage of Participants Who Did Not Require a Platelet Transfusion or Any Rescue Procedure for Bleeding After Randomization Following a Scheduled ProcedureRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: avatrombopag (lower baseline platelet count), placebo (lower baseline platelet count), avatrombopag (higher baseline platelet count), placebo (higher baseline platelet count) | Thrombocytopenia Associated With Liver Disease | 231 | 2017-01-26actual | — | 2018-02-27 |
| Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid TumorsNCT02686164results2019-08-28AUC(0-24): Area Under the Concentration-time Curve From Time Zero to 24 Hours Postdose for Midazolam and 1'-HydroxymidazolamOpen-label · Treatment | Phase 1 | Completed | Drug: Lenvatinib, Midazolam | Tumors | 51 | 2017-01-04actual | — | 2019-08-28 |
| Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast CancerNCT02481050results2018-11-15Objective Response Rate (ORR) by Investigator AssessmentOpen-label · Treatment | Phase 2 | Completed | Drug: Eribulin Mesylate | Breast Cancer | 58 | 2016-12-31actual | — | 2018-11-15 |
| A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy SubjectsNCT02859207Mean maximum plasma concentration (Cmax) of E2609Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E2609 | Early Alzheimer's Disease | 32 | 2016-12-06actual | — | 2017-06-08 |
| Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy SubjectsNCT02947711Number of participants with any adverse event (AE) and any serious adverse event (SAE)Open-label · Treatment | Phase 1 | Completed | Drug: E2027, Diltiazem ER | Healthy Subjects | 16 | Nov 2016actual | — | 2017-03-07 |
| Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination ChemotherapyNCT02579616results2020-12-23Objective Response Rate (ORR)Open-label · Treatment | Phase 2 | Completed | Drug: Lenvatinib | Biliary Tract Cancer | 29 | 2016-11-22actual | — | 2020-12-23 |
| A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular CarcinomaNCT01761266results2018-09-25Overall Survival (OS)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Lenvatinib, Sorafenib | Hepatocellular Carcinoma (HCC) | 954 | 2016-11-13actual | — | 2022-04-05 |
| Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)NCT02430714observationalNumber of participants with adverse events (AEs)/adverse drug reactions (ADRs) | — | Completed | Drug: Lenvatinib | Thyroid Neoplasms | 629 | 2016-11-06actual | — | 2020-01-09 |
| An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy SubjectsNCT02427607results2018-07-02Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of PerampanelOpen-label · Treatment | Phase 3 | Completed | Drug: Perampanel | Epilepsy | 7 | 2016-09-21actual | — | 2018-07-02 |
| A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.NCT02094053Changes in total scores from baseline using Body Functionality Checklist (psychosomatic function questionnaire) in subjects with Down syndrome having regression symptoms and disabled activities of daily living (ADL), relative to placebo.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: E2020-Donepezil hydrochloride, E2020-Donepezil hydrochloride, Placebo | Down Syndrome | 36 | 2016-09-16actual | — | 2017-08-22 |
| To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset SeizuresNCT02220972Change from baseline in latency to persistent sleep (LPS) using Polysomnography (PSG)Randomized · Double-masked · Treatment | Phase 4 | Withdrawn | Drug: Perampanel, Placebo | Epilepsy, Partial | 0 | Aug 2016 | — | 2015-02-10 |
| Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy SubjectsNCT02809768Mean maximum observed concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Avatrombopag, Fluconazole, Itraconazole, Rifampin | Healthy Participants | 48 | Aug 2016actual | — | 2017-03-09 |
| A Study of E6011 in Japanese Subjects With Rheumatoid ArthritisNCT02196558results2020-08-13Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: E6011 | Arthritis, Rheumatoid | 53 | 2016-08-12actual | — | 2020-08-13 |
| A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)NCT00903786results2018-08-29Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of PerampanelOpen-label · Treatment | Phase 2 | Completed | Drug: perampanel | Refractory Partial Seizures | 21 | 2016-08-08actual | — | 2018-08-29 |
| A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103)NCT01773434Tolerability and SafetyOpen-label · Treatment | Phase 1 | Completed | Drug: MORAb-004 | Solid Tumor | 46 | Jul 2016actual | — | 2016-11-10 |
| Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade GliomaNCT02300506observationalSurvival rate | — | Completed | Other: No intervention | Malignant Glioma | 507 | 2016-07-10actual | — | 2018-11-05 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult SubjectsNCT02415790Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: E2027, E2027 matching placebo | Healthy Participants | 112 | Jun 2016actual | — | 2017-03-08 |
| Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With EpilepsyNCT02736162observationalRetention rate | — | Completed | Other: No treatment (intervention) was administered | Epilepsy, Partial-Onset Seizures, Primary Generalized Tonic-Clonic Seizures | 61 | Jun 2016actual | — | 2017-03-09 |
| A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease PatientsNCT02135107results2018-11-19Rate of Non-recurrence at Week 52Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Rabeprazole, Rabeprazole, Rabeprazole, Rabeprazole | Gastroesophageal Reflux Disease | 517 | May 2016actual | — | 2023-06-22 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's DiseaseNCT02249078Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of the short-term safety and tolerability of E6011Randomized · Double-masked · Treatment | Phase 1 | Withdrawn | Drug: E6011, Placebo | Crohn's Disease | 0 | Mar 2016 | — | 2015-11-05 |
| Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter PyloriNCT01264822observationalResponse rate of gastric low-grade MALT lymphoma by eradication of Helicobacter pylori | — | Completed | Drug: Rabeprazole Sodium | Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive | 108 | 2016-02-29actual | — | 2017-02-27 |
| Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the LungNCT01877083results2019-08-13Objective Response Rate (ORR)Open-label · Treatment | Phase 2 | Completed | Drug: Lenvatinib | KIF5B-RET-Positive Adenocarcinoma of the Lung | 25 | 2016-02-03actual | — | 2019-08-13 |
| E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and NeckNCT01332266results2022-01-03Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0)Randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: E7050, Cetuximab | Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck | 95 | 2016-01-31actual | — | 2022-01-03 |
| This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including LymphomasNCT02171260results2018-12-24Maximum Tolerated Dose (MTD) of Eribulin MesylateOpen-label · Treatment | Phase 1 | Completed | Drug: Eribulin Mesylate | Pediatrics, Solid Tumors | 23 | 2016-01-28actual | — | 2019-01-15 |
| A Study of APD356 (Lorcaserin) in Healthy Japanese Adult SubjectsNCT02192515Safety as assessed by adverse events (AEs), clinical laboratory tests, vital signs, body weight and ECGsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: APD356 10 mg, APD356 XR-20 mg, APD356 10 mg matching Placebo, APD356 XR-20 mg matching Placebo, APD356 20 mg, APD356 20 mg matching Placebo, APD356 XR-20 mg (orange tablet), APD356 XR-20mg (orange tablet, fed state) | Healthy Subjects | 40 | Nov 2015actual | — | 2016-02-10 |
| Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic DrugsNCT01405053results2019-08-06Child Behavior Checklist (CBCL) Total Problem T-scores at the End of 2-year Treatment PeriodRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Rufinamide, Any other approved Antiepileptic Drug | Lennox-Gastaut Syndrome | 37 | 2015-11-02actual | — | 2019-08-06 |
| An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid TumorsNCT01945710results2019-07-23Maximum Tolerated Dose (MTD) of Eribulin-LFNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Eribulin-LF | Solid Tumors | 62 | Oct 2015actual | — | 2019-07-23 |
| European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS)NCT01991041observationalSafety during the use of rufinamide and other anti-epileptic drugs | — | Completed | — | Lennox-Gastaut Syndrome | 109 | Oct 2015actual | — | 2016-05-04 |
| Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational RegistryNCT02443428observationalNumber of participants with adverse events (AEs) and serious adverse events (SAEs) | — | Completed | — | Breast Cancer | 77 | Oct 2015actual | — | 2016-04-15 |
| Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's DiseaseNCT01251718observationalADAS-Jcog (test of cognitive function) | — | Completed | Drug: donepezil hydrochloride | Alzheimer's Disease | 894 | 2015-10-14actual | — | 2023-07-24 |
| Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-NCT01129596observationalThe transition of clinical condition is evaluated comparing the result of HDS-R,MMSE with the time of study initiation | — | Completed | Drug: donepezil hydrochloride | Alzheimer's Disease | 10,238 | 2015-09-25actual | — | 2018-11-05 |
| E7777 for the Treatment of Patients With Peripheral T-Cell LymphomaNCT01401530results2018-11-23Maximum Tolerated Dose (MTD) and Recommended Dose (RD)Open-label · Treatment | Phase 1 | Completed | Biological: denileukin diftitox (E7777) | Peripheral T-Cell Lymphoma | 13 | Aug 2015actual | — | 2018-11-23 |
| An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid CancerNCT02211222expanded access | — | Approved for marketing | Drug: Lenvatinib | Differentiated Thyroid Cancer | — | Aug 2015 | — | 2016-03-16 |
| An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid TumorsNCT01618136Phase 1 To determine the maximum tolerated dose of E7449 as a single agentNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: E7449 alone, E7449 plus TMZ, E7449 plus carboplatin and paclitaxel | Malignant Solid Tumour, Ovarian Cancer, Triple Negative Breast Cancer, Advanced Melanoma, B-cell Malignancy, Low-grade | 41 | Jul 2015actual | — | 2023-06-18 |
| Single/ Multiple-Dose Study of E6007 in Healthy Japanese Male SubjectsNCT02268838Safety and tolerability of E6007 as a measure of Adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: E6007, E6007 matching placebo | Healthy Volunteers | 24 | Jul 2015actual | — | 2016-01-20 |
| A Study of E7080 in Subjects With Advanced Thyroid CancerNCT01728623results2020-08-14Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 2 | Completed | Drug: E7080 capsule | Thyroid Cancer | 51 | 2015-07-09actual | — | 2020-08-14 |
| E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular CarcinomaNCT01271504results2021-04-08Phase 1b: Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT)Randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: Sorafenib, Sorafenib | Hepatocellular Carcinoma | 102 | 2015-06-23actual | — | 2021-05-12 |
| Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal CancerNCT01347645results2022-11-25Phase 1b: Maximum Tolerated Dose (MTD) of E7820 With Irinotecan as Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0Randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: The study was terminated by the Sponsor due to E7820 plus irinotecan being potentially inferior to FOLFIRI | Drug: FOLFIRI, E7820 | Colon Cancer, Rectal Cancer | 82 | 2015-06-22actual | — | 2023-06-22 |
| Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical PracticeNCT02162264observationalChange From Baseline in the Mini-Mental State Examination (MMSE) Score | — | Completed | Drug: Donepezil Hydrochloride | Alzheimer's Disease | 8,662 | 2015-05-30actual | — | 2018-09-07 |
| Post-marketing Surveillance of DC Bead in Patients With Hepatocellular CarcinomaNCT02269995observationalSafety and Tolerability as measured by Adverse Events | — | Completed | Device: E7040 | Hepatocellular Carcinoma | 300 | 2015-05-14actual | — | 2018-11-05 |
| Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder CancerNCT01126749results2022-02-28Phase 1b: Number of Participants With Dose-limiting Toxicity (DLT) as Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0Randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Study was terminated as per sponsor's decision | Drug: Gemcitabine, E7389, Cisplatin | Bladder Cancer | 92 | 2015-05-08actual | — | 2022-02-28 |
| Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's DiseaseNCT02162251observationalInvestigations on adverse events and adverse drug reactions | — | Completed | Drug: Donepezil Hydrochloride | Alzheimer's Desease | 3,482 | 2015-05-01actual | — | 2018-09-07 |
| A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of AgeNCT02398669Plasma PK profile of lorcaserin and its primary metabolites (M1 and M5)Open-label · Treatment | Phase 1 | Completed | Drug: Lorcaserin hydrochloride | Obesity | 10 | Apr 2015actual | — | 2015-11-03 |
| Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia DisorderNCT02350309results2020-01-18Mean Change From Baseline in the Average Sleep Onset Latency (SOL) From Modified-Multiple Sleep Latency Test (M-MSLT) for Each Treatment in Treatment Periods 1 to 3Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Lemborexant 5 mg, Lemborexant 10 mg, Lemborexant-matched placebo., Flurazepam 30 mg | Insomnia Disorder | 69 | 2015-04-21actual | — | 2020-01-18 |
| Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV MelanomaNCT01127451results2022-04-13Percentage of Participants With Immune-related Overall Response Rate (irORR)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Denileukin diftitox | Stage IIIC Melanoma, Stage IV Melanoma | 75 | 2015-04-07actual | — | 2022-04-13 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and ThrombocytopeniaNCT02227693results2019-02-28Percentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L and at Least 20 x 10^9/L Increase From Baseline at Visit 4Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: avatrombopag, Placebo | Thrombocytopenia Associated With Chronic Liver Disease | 39 | 2015-04-01actual | — | 2019-02-28 |
| An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer RefractoryNCT01240421expanded access | — | Approved for marketing | Drug: Eribulin Mesylate | Metastatic Breast Cancer | — | Mar 2015 | — | 2015-05-22 |
| A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's DiseaseNCT02094729Number of Participants with Adverse Events as a Measure of Safety and TolerabilityRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: BAN2401 2.5 mg/kg, BAN2401 5 mg/kg, BAN2401 10 mg/kg, Placebo | Alzheimer's Disease | 26 | Mar 2015actual | — | 2015-06-08 |
| Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia PatientsNCT02455271observationalAssessment of overall improvement | — | Completed | Drug: Eszopiclone | Insomnia | 438 | 2015-03-30actual | — | 2018-09-07 |
| A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)NCT01433991results2021-06-08Phase 1b: Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT)- Combination TreatmentRandomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Study was terminated by the sponsor early at the end of Phase 1b due to a change in corporate strategy. | Drug: Golvatinib, Lenvatinib, Lenvatinib | Advanced Solid Tumors | 30 | 2015-03-18actual | — | 2021-06-08 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese SubjectsNCT02289599Number of adverse events/serious adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: E2307, E2307 Matching Placebo | Healthy Subjects | 24 | Feb 2015actual | — | 2016-01-18 |
| Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's DiseaseNCT01539031The Severe Impairment Battery (SIB)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: E2020, E2020 | Alzheimer's Type Dementia | 351 | Jan 2015actual | — | 2023-06-18 |
| Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled StudyNCT01645800Acute exacerbation of COPDRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Lysozyme hydrochloride, Placebo | COPD | 408 | Jan 2015actual | — | 2015-10-21 |
| Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue SarcomaNCT01327885results2017-02-28Overall Survival (OS)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Eribulin mesylate 1.4 mg/m^2 intravenous, Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV | Soft Tissue Sarcoma | 452 | 2015-01-02actual | — | 2023-06-22 |
| A Study of E2022 Tape Formulation (Overlay-integrated E2022 18 mg Tape Formulation) for Different Application Sites and Intervals in Japanese Healthy Elderly MalesNCT02225288Number and frequency of adverse eventsRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: E2022 | Healthy Subjects | 48 | Dec 2014actual | — | 2015-04-02 |
| A Study to Demonstrate Bioequivalence Between a 12-mg Dose of an Oral Suspension Formulation of Perampanel and a 12-mg Tablet Formulation of Perampanel Under Fasted and Fed Conditions in Healthy SubjectsNCT02279485Pharmacokinetics of Perampanel: AUC(0-t)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Perampanel | Healthy Subjects | 100 | Dec 2014actual | — | 2015-11-03 |
| An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)NCT01458249results2016-03-28Progression-free Rate at 12 Weeks (PFR12wks)Open-label · Treatment | Phase 2 | Completed | Drug: eribulin mesylate | Soft Tissue Sarcoma | 52 | Nov 2014actual | — | 2016-03-28 |
| Investigation of the Safety and Efficacy of Eszopiclone in Insomnia PatientsNCT02452684observationalAssessment of overall improvement | — | Completed | Drug: Eszopiclone | Insomnia | 4,876 | 2014-11-11actual | — | 2018-09-07 |
| A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell LymphomaNCT01355783To evaluate whether treatment of E7777 in combination with CHOP chemotherapy has superior efficacy compared with CHOP alone in improving progression-free survival (PFS) in first line treatment of subjects with peripheral T-cell lymphomaRandomized · Open-label · Treatment | Phase 3 | Withdrawn | Drug: E7777 | Peripheral T-Cell Lymphoma | 0 | Oct 2014 | — | 2013-11-18 |
| A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy SubjectsNCT02222324Change from baseline in QTcF obtained from ECGs extracted from the Holter recordingsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Placebo, E2609, Moxifloxacin | Healthy Subjects | 60 | Oct 2014actual | — | 2015-11-03 |
| Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast CancerNCT01328249results2018-09-26Percentage of Participants With FeasibilityOpen-label · Treatment | Phase 2 | Completed | Drug: eribulin mesylate | HER2-normal | 81 | 2014-10-27actual | — | 2019-08-20 |
| Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial SeizuresNCT00735397results2016-01-26Number of Participants With Treatment-emergent Non-Serious Adverse Events (AEs) and Treatment-emergent Serious Adverse Events (SAEs)Open-label · Treatment | Phase 3 | Completed | Drug: perampanel | Epilepsy | 1,218 | Sep 2014actual | — | 2016-03-14 |
| A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset SeizuresNCT01618695results2020-06-05Core Phase: Percent Change in Seizure Frequency (For All Partial Seizures) Per 28 Days in the Randomization Phase Relative to Pre-randomization Phase (Baseline)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Perampanel, Placebo | Partial-onset Seizures | 940 | 2014-09-15actual | — | 2021-07-29 |
| A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese AdultsNCT01987427results2019-09-30Percentage of Participants Reporting at Least One of Nine Adverse Events (AEs) of Main Interests That May Related to Serotonergic ReactionRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: lorcaserin + phentermine placebo, lorcaserin + phentermine-HCl + phentermine placebo, lorcaserin + phentermine-HCl | Chronic Weight Management | 344 | Aug 2014actual | — | 2019-09-30 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White SubjectsNCT02207790Pharmacokinetics of E2609: CmaxRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: E2609, Placebo | Healthy Subjects | 32 | Aug 2014actual | — | 2015-11-03 |
| Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy VolunteersNCT02792829results2019-03-14Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC(0-t))Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Lenvatinib | Healthy Volunteers | 60 | Aug 2014actual | — | 2019-03-14 |
| A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's DiseaseNCT01404169The change in the total Severe Impairment Battery (SIB) score at Week 24Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: E2020, Placebo | Alzheimer's Type Dementia | 260 | Jul 2014actual | — | 2017-03-08 |
| An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal FunctionNCT01418677To study the influence of moderate and severe renal impairment on the Composite of Pharmacokinetics of HALAVEN following a single intravenous administration to subjects with cancer.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E7389, E7389, E7389 | Unspecified Adult Solid Tumor, Protocol Specific | 19 | Jul 2014actual | — | 2016-05-17 |
| An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of 14C-Perampanel in Healthy Male SubjectsNCT02116907Mass balance recovery of 14C as a cumulative percent of the radiolabeled dose and the identification and quantification of metabolites in humans in vivo after administration of a single dose of radiolabeled 14C-perampanel in healthy male subjects.Open-label · Treatment | Phase 1 | Completed | Drug: E2007 | Healthy Subjects | 7 | Jul 2014actual | — | 2015-11-03 |
| A Confirmation Study of Eribulin in Combination With CapecitabineNCT01323530results2021-01-11Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0)Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: Eribulin mesylate, Capecitabine | Metastatic Breast Cancer | 76 | 2014-07-28actual | — | 2021-01-11 |
| Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)NCT02300532observationalNumber of Adverse Events/Serious Adverse Events | — | Completed | Other: No intervention | Malignant Glioma | 561 | 2014-07-10actual | — | 2017-02-27 |
| 4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial SeizuresNCT00368472results2015-12-10Number of Participants With Treatment-emergent Non-serious Adverse Events (AEs) and Treatment-emergent Serious Adverse Events (SAEs)Open-label · Treatment | Phase 2 | Completed | Drug: Perampanel | Epilepsy | 138 | Jun 2014actual | — | 2015-12-10 |
| E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV MelanomaNCT01133977results2016-10-10Dose Limiting Toxicity (DLT) of Lenvatinib Administered in Combination With Dacarbazine (for Phase 1b)Randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: Lenvatinib, Lenvatinib, Dacarbazine | Stage IV Melanoma | 97 | Jun 2014actual | — | 2016-10-10 |
| A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White SubjectsNCT02039076Pharmacokinetic (PK) profiles of avatrombopagRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: avatrombopag | Thrombocytopenia | 48 | Jun 2014actual | — | 2014-12-18 |
| Extended Treatment in Metastatic Breast Cancer With EribulinNCT02769364observationalOverall survival | — | Completed | — | Breast Cancer | 45 | Jun 2014actual | — | 2023-07-24 |
| Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)NCT00946153results2019-02-01Phase 1: Maximum Tolerated Dose (MTD) of LenvatinibNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: Lenvatinib | Hepatocellular Carcinoma | 66 | 2014-06-15actual | — | 2019-02-01 |
| A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted TreatmentNCT01136733results2019-02-27Phase 1b: Number of Participants With Dose-limiting Toxicity (DLT)Randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: Lenvatinib, Everolimus | Metastatic Renal Cell Carcinoma | 173 | 2014-06-13actual | — | 2019-02-27 |
| A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic SeizuresNCT01393743results2016-01-11Median Percent Change in Primary Generalized Tonic Clonic Seizure Frequency (PGTC) Per 28 Days During the Titration and Maintenance Periods (Combined) Relative to Baseline (Prerandomization) - (for Core Study)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Perampanel, Placebo comparator | Seizure Disorder Generalized Tonic Clonic | 163 | May 2014actual | — | 2017-08-28 |
| Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic DrugsNCT01527006results2015-08-28Apparent Clearance (CL/F) of Perampanel [Core Study]Open-label · Treatment | Phase 2 | Completed | Drug: perampanel | Central Nervous System | 63 | May 2014actual | — | 2016-07-12 |
| A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White SubjectsNCT02039089Pharmacokinetic (PK) profiles of E2006Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: E2006 2.5 mg, E2006 10 mg, E2006 25 mg, Placebo | Healthy Volunteers | 32 | May 2014actual | — | 2015-11-03 |
| A Study to Determine the Effect of a High-Fat Meal on the Rate and Extent of E2006 Absorption in Healthy SubjectsNCT02089412Pharmacokinetics of E2006: AUC(t-0)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E2006 | Healthy Subjects | 59 | May 2014actual | — | 2015-11-03 |
| A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung CancerNCT01454934results2017-03-01Overall Survival (OS)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Eribulin, TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed | Non-Small Cell Lung Cancer (NSCLC) | 540 | 2014-05-30actual | — | 2023-06-22 |
| An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid TumorsNCT01773421results2020-01-18Treatment Phase Part A: AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for E7820Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E7820, E7820 | Advanced Solid Tumors | 45 | 2014-04-30actual | — | 2023-06-22 |
| An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male SubjectsNCT02046213Pharmacokinetics: Excretion of E2006: urine/feces concentrationNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E2006 | Metabolism and Excretion | 16 | Apr 2014actual | — | 2015-11-03 |
| A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or DonepezilNCT02055703To evaluate the pharmacokinetics (PK) of single oral doses of E2609 and metabolites in subjects dosed alone or in combination with either rifampin or itraconazoleRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: E2609, itraconazole, rifampin, digoxin, donepezil | Healthy Subjects | 195 | Apr 2014actual | — | 2015-11-03 |
| A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or BupropionNCT02085967Pharmacokinetics of E2006 and its major metabolites, M4, M9, and M10 (Part A), and midazolam, bupropion, and the hydroxylated metabolite of bupropion (Part B): AUC(0-t)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: rifampin 600 mg, itraconazole 200 mg, midazolam 2 mg with bupropion 75 mg, E2006 | Healthy Subjects | 106 | Apr 2014actual | — | 2015-11-03 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic InsomniaNCT01995838results2020-01-31Probability of Having Utility Function Greater Than (>) 1 Based on Bayesian AnalysisRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: E2006, Placebo | Chronic Insomnia, Adults, Elderly | 291 | 2014-04-29actual | — | 2020-01-31 |
| Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid ArthritisNCT01850966observationalDisease Activity Score (DAS28) for Rheumatoid Arthritis (EULAR Response Criteria) | — | Completed | Drug: Iguratimod | Rheumatoid Arthritis | 2,747 | 2014-04-13actual | — | 2018-11-05 |
| A Study in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT00444613Survival rateRandomized · Double-masked · Treatment | Phase 2/3 | Completed | Drug: E0302 (mecobalamin), E0302 (mecobalamin), Placebo | Amyotrophic Lateral Sclerosis (ALS) | 373 | Mar 2014actual | — | 2023-06-18 |
| A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)NCT01830400observationalRetention Rate of Eslicarbazepine Acetate (ESL) After 6 months from Baseline | — | Completed | Drug: Eslicarbazepine Acetate tablets | Partial Onset Seizures | 254 | Mar 2014actual | — | 2015-08-19 |
| A Multiple Dose Pharmacokinetic Study of Perampanel in Korean Healthy SubjectsNCT02020486Pharmacokinetics (PK) of perampanel in Korean healthy male subjectsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Perampanel, Perampanel | Healthy | 20 | Mar 2014actual | — | 2015-03-03 |
| Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501NCT01355289results2018-02-22Number of Participants Who Achieved Platelet Response (Greater Than or Equal to 100 x 10^9/L) by Day 21 of Treatment Period A1 of Core StudyRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Avatrombopag, Placebo, Pegylated interferon (PEG-IFN), Telaprevir, Ribavirin | Thrombocytopenia | 65 | Feb 2014actual | — | 2018-02-22 |
| Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III MelanomaNCT01605162The Progression Free Survival-6m rate defined as the proportion of subjects that are alive and progression-free at 6-months from the date of first dosing based on RECIST 1.1.Open-label · Treatment | Phase 2 | Terminated | Drug: TMZ, E7016 | Wild Type BRAF Stage IV Melanoma, Unresectable Stage III Melanoma | 8 | Feb 2014actual | — | 2016-07-28 |
| A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different TreatmentsNCT01529112results2016-02-18Overall Survival (OS)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Lenvatinib, Lenvatinib matched placebo, BSC | Non-Small Cell Lung Cancer | 135 | 2014-01-21actual | — | 2017-09-26 |
| Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)NCT01398410results2015-11-16Percentage of Participants With Treatment Emergent Adverse Events (AEs)Randomized · Open-label · Prevention | Phase 2/3 | Completed | Drug: Rabeprazole, Rabeprazole | Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin | 405 | Dec 2013actual | — | 2015-12-21 |
| A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous MalformationNCT01677624results2016-02-22Success Rate of Embolization in the Target VesselOpen-label · Treatment | Phase 3 | Completed | Device: E7040 | Hypervascular Tumor and Arteriovenous Malformation | 28 | Dec 2013actual | — | 2016-02-22 |
| Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum SymptomNCT01715493Change of several inflammatory or biochemical marker concentration in inducted sputumRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: lysozyme 90 mg, Placebo | Chronic Obstructive Pulmonary Disease, Asthma | 48 | Dec 2013actual | — | 2014-07-18 |
| Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of AgeNCT02022956Assess the single-dose pharmacokinetic (PK) parameters of lorcaserin and a primary metabolites (M1 and M5) in obese adolescent subjects ages 12-17 (inclusive)Open-label · Other | Phase 1 | Completed | Drug: Lorcaserin | Pharmacokinetics in Obese Adolescents | 8 | Dec 2013actual | — | 2019-09-17 |
| A Phase 1 Study of Single-dose Subcutaneous E6011 in Japanese Healthy Adult Male SubjectsNCT02146261Pharmacokinetics of E6011: Maximum Concentration (Cmax)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: E6011, Placebo | Healthy | 32 | Dec 2013actual | — | 2014-10-22 |
| Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic MelanomaNCT01335009results2021-09-01Percentage of Participants With Progression-free Survival (PFS) at Week 24Randomized · Open-label · Treatment | Phase 2 | Completed | Biological: MORAb-004 (monoclonal antibody) | Metastatic Melanoma | 76 | 2013-12-02actual | — | 2021-09-01 |
| Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)NCT01438840results2018-01-05Number of Weeks With Platelet Count Greater Than or Equal to 50 x 10^9/L During 6-Month Treatment PeriodRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Avatrombopag, Placebo, Standard of care | Chronic Thrombocytopenia, Immune Thrombocytopenia | 49 | Nov 2013actual | — | 2018-02-05 |
| An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male SubjectsNCT01975636Pharmacokinetics: Elimination of E2609: urine/feces concentrationOpen-label · Treatment | Phase 1 | Completed | Drug: E2609 | Metabolism and Elimination | 113 | Nov 2013actual | — | 2016-01-08 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)NCT01321554results2016-12-12Progression Free Survival (PFS)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Lenvatinib, Placebo, Lenvatinib | Thyroid Cancer | 392 | 2013-11-15actual | — | 2023-06-22 |
| A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)NCT01433978results2018-02-06Change From Baseline in Local Platelet Count for the 6 Month Treatment PeriodRandomized · Triple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Study was terminated early due to significant enrollment challenges. | Drug: Eltrombopag, Avatrombopag, Standard of care | Idiopathic Thrombocytopenic Purpura | 24 | Sep 2013actual | — | 2018-02-06 |
| Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)NCT01600859Percent change from baseline in cerebrospinal fluid amyloid-beta levelsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: E2609, Placebo for E2609 | Alzheimer's Disease | 65 | Sep 2013actual | — | 2016-12-30 |
| A Long Term Extension Study of E2080 in Lennox-Gastaut PatientsNCT01151540results2019-03-11Number of Participants With Adverse Events as a Measure of Safety and Tolerability of RufinamideOpen-label · Treatment | Phase 3 | Completed | Drug: Rufinamide | Lennox-Gastaut Syndrome | 54 | Aug 2013actual | — | 2019-03-11 |
| A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast CancerNCT01432886results2015-03-30Number of Participants With Dose Limiting Toxicity (DLT)Open-label · Treatment | Phase 1 | Completed | Drug: E7389 | Breast Cancer | 12 | Aug 2013actual | — | 2016-10-07 |
| A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)NCT01731275Number of Participants with Adverse EventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: E6011, E6011 Matching Placebo | Healthy Male Volunteers | 64 | Aug 2013actual | — | 2014-02-14 |
| Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy VolunteersNCT02723630results2019-03-14Area Under the Plasma Concentration-Time Curve From Zero Time (Predose) to Time of Last Quantifiable Concentration (AUC(0-t))Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Lenvatinib 10 mg | Healthy Volunteers | 60 | Aug 2013actual | — | 2019-03-14 |
| A Single-dose Study in Healthy Japanese Male Adults to Evaluate Pharmacokinetics and Pharmacodynamics of E5501 5 mg Tablet (Study E5501-J081-015)NCT01774773Pharmacokinetic Parameter: Maximal Drug Concentration (Cmax) Under Fed ConditionsRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg, Group B: E5501 20mg, then 40mg, then 5 mg, then 5mg, Group C: E5501 40mg, then 5mg, then 20 mg, then 5mg | Healthy | 15 | Jul 2013actual | — | 2014-02-03 |
| Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) SubjectsNCT01177540results2022-06-28Percentage of Participants With Morphologic Complete Remission (CR)Randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: The study was terminated early due to enrollment difficulties and the futility of observing differences in remission rate between treatment arms. | Drug: Decitabine, Decitabine | Pediatric Acute Myelogenous Leukemia (AML) | 25 | 2013-07-19actual | — | 2022-06-28 |
| A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in AdolescentsNCT01161524results2019-05-15Change From Baseline to Week 19 in Cognition Drug Research (CDR) System Global Cognition Score (Core Study)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Perampanel, Placebo | Epilepsy | 133 | Jun 2013actual | — | 2019-05-15 |
| A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)NCT01830868observationalRetention Rate of Zonisamide (ZNS) after 6 months from Baseline | — | Completed | Drug: Zonisamide tablets | Partial Onset Seizures | 104 | Jun 2013actual | — | 2023-06-18 |
| 2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly SubjectsNCT01673451Incidence of Adverse events (AEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: E2006, Placebo comparator | CNS | 24 | May 2013actual | — | 2013-10-11 |
| A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast CancerNCT00879086results2021-12-01Percentage of Participants With Treatment-Emergent Neuropathy Adverse Events (AEs)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Eribulin Mesylate, Ixabepilone | Breast Cancer | 104 | 2013-04-30actual | — | 2023-06-22 |
| An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV MelanomaNCT01136967results2016-03-16Objective Response Rate (ORR)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Lenvatinib | Unresectable Stage III, Stage IV Melanoma | 182 | Apr 2013actual | — | 2019-11-13 |
| E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric CancerNCT01355302results2017-03-13Area Under The Concentration-Time Curve (AUC) From 0 to 24 Hours of GolvatinibRandomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Sites not recruiting | Drug: E7050, cisplatin, capecitabine | Advanced or Metastatic Solid Tumors, Previously Untreated Gastric Cancer | 7 | Apr 2013actual | — | 2017-05-15 |
| A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals in Japanese Healthy Elderly MalesNCT01843556Number and frequency of adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E2022 Tape Formulation | Healthy Elderly Male | 48 | Apr 2013actual | — | 2023-06-18 |
| Dose-Finding Study of E7070 in Combination With IrinotecanNCT00060567To determine the Maximum tolerated dose of E7070 in combination with irinotecan in patients with GI tract, pancreatic or lung tumors.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E7070 + irinotecan combination, Irinotecan + E7070 combination, Irinotecan + E7070 combination | Cancer | 88 | Mar 2013actual | — | 2023-06-18 |
| Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast CancerNCT01269346results2017-03-30Objective Response RateOpen-label · Treatment | Phase 2 | Completed | Drug: Eribulin Mesylate | Breast Cancer | 52 | Mar 2013actual | — | 2023-06-22 |
| A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension PhaseNCT01278407results2015-11-30Change From Baseline in Mini-Mental State Examination (MMSE) ScoreRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Donepezil 5 mg, Donepezil 10 mg, Donepezil matched placebo | Dementia With Lewy Bodies (DLB) | 142 | Mar 2013actual | — | 2023-06-29 |
| Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)NCT01397448results2014-10-23Cumulative Recurrent Rates of Gastric or Duodenal UlcersRandomized · Quadruple-masked · Prevention | Phase 2/3 | Completed | Drug: E3810, E3810, Teprenone | Gastric or Duodenal Ulcers Caused by Low-dose Aspirin | 472 | Mar 2013actual | — | 2014-11-26 |
| A Study in Subjects With Recurrent Malignant GliomaNCT01137604results2016-05-23Progression Free Survival (PFS) Rate at Month 6Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Lenvatinib, Bevacizumab | Glioma | 151 | 2013-03-19actual | — | 2022-09-29 |
| Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux EsophagitisNCT01321567observationalNumber of subjects with improvement based on health related Quality of Life (QOL) questionnaire | — | Completed | Drug: rabeprazole sodium | Refractory Reflux Esophagitis | 2,157 | 2013-03-01actual | — | 2023-07-24 |
| Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric UlcerNCT01190657Endoscopic results of ulcer lesionNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Selbex, Selbex | Acute Gastritis, Gastric Ulcer | 1,184 | Feb 2013actual | — | 2013-04-01 |
| The Effect of Vitamin K2 on Bone TurnoverNCT00548509Gamma-carboxylationRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Menatetrenone (Vitamin K2) | Osteoporosis | 131 | Jan 2013actual | — | 2018-10-29 |
| Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor PolyneuropathyNCT00927914Peroneal motor nerve conduction velocity: the mean of duplicate bilateral recordings made within 1-21 days of each other.Randomized · Double-masked · Treatment | Phase 2/3 | Completed | Drug: Ranirestat, Placebo | Mild to Moderate Diabetic Sensorimotor Polyneuropathy | 800 | Jan 2013actual | — | 2019-02-21 |
| A Study of MORAb-003 in Patients With Solid TumorNCT01049061To investigate dose-limiting toxicity and estimate maximum tolerated dose.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: MORAb-003 | Neoplasms, Solid Tumor | 16 | Jan 2013actual | — | 2020-06-11 |
| A Study to Evaluate the Safety and Efficacy of Zonisamide an Antiepileptic Drug as Monotherapy or Adjunctive Therapy in Treatment of Adult Patients With Partial, Generalized or Combined Seizures.NCT01283256observationalAssess safety with zonisamide therapy in adult patients with different seizure types | — | Completed | Drug: zonisamide | Partial, Generalized and Combined Seizures | 655 | Jan 2013actual | — | 2014-01-27 |
| A Phase I Study of E7050 in Subjects With Solid TumorsNCT01428141Determination of the maximum tolerated dose (MTD)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E7050 | Solid Tumor, Gastric Cancer | 18 | Jan 2013actual | — | 2014-02-14 |
| A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat MealNCT01759394Area under the plasma concentration-time course profile From Time = 0 to time extrapolated to infinity (AUC [0-inf])Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Avatrombopag maleate 40 mg | Healthy Volunteers | 36 | Jan 2013actual | — | 2013-10-31 |
| Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung CancerNCT01126736results2022-08-04Phase 1b: Number of Participants With Dose-Limiting Toxicity (DLTs)Randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: eribulin mesylate, pemetrexed, Eribulin mesylate (eribulin; E7389) | Non Small Cell Lung Cancer | 98 | 2012-12-31actual | — | 2023-06-22 |
| An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on AbsorptionNCT01716897AUC(0-inf) ratio, new tablet vs. capsuleRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: E2609 | Alzheimer's Disease | 18 | Dec 2012actual | — | 2013-05-22 |
| Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)NCT01463891observationalEffectiveness Diagnosed by Imaging | — | Completed | Drug: Eribulin Mesylate | Inoperable or Recurrent Breast Cancer | 963 | 2012-12-26actual | — | 2023-07-24 |
| Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast CancerNCT01439282results2016-06-20Percentage of Participants Who Achieved the Target Relative Dose Intensity (RDI) of 85%Open-label · Treatment | Phase 2 | Completed | Drug: eribulin mesylate, capecitabine | Estrogen Receptor Positive Tumor, Breast Cancer | 77 | Nov 2012actual | — | 2023-06-22 |
| A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose StudyNCT01230853Single Ascending Dose (SAD)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Active Comparator: A, Placebo Comparator B, Active Comparator B, Placebo Comparator A | Alzheimer's Disease | 80 | Oct 2012actual | — | 2020-11-23 |
| A Study to Assess the Transfer of Fospropofol and Its Active Metabolite, Propofol, to Breast Milk Following Administration of LUSEDRA to Lactating Women Undergoing a Needed ProcedureNCT01309984Total amount (Ae0-24) of propofol transferred to breast milk in 24 hours.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Lusedra, Propofol | Lactating Women | 10 | Oct 2012actual | — | 2015-11-03 |
| Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule FormulationsNCT01673880Plasma concentrations of E2006 of tablet vs. capsule formulationsRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: E2006 | Insomnia | 40 | Oct 2012actual | — | 2013-05-22 |
| A Phase 1 Comparative Study of E2022 Current and New Patch FormulationsNCT02042729Number of Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E2022- Current Formula Tape, E2022- New Formula Tape, E2022 Matching Placebo- Current Formula Tape, E2022 Matching Placebo- New Formula Tape | Healthy | 34 | Oct 2012actual | — | 2014-02-21 |
| A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy SubjectsNCT02199379Pharmacokinetics of lenvatinib: CmaxNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Lenvatinib | Renal Impairment, Disease Severity | 26 | Oct 2012actual | — | 2015-04-14 |
| A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid TumorsNCT00869895Maximum Tolerated Dose: the highest dose at which no more than 1 out of 6 patients experiences Dose Limiting Toxicity (DLT) during Cycle 1.Open-label · Treatment | Phase 1 | Completed | Drug: E7050 | Cancer | 60 | Aug 2012actual | — | 2016-01-29 |
| A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006NCT01463098results2020-01-18Part A: Number of Participants With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: E2006 1.0 mg, E2006 2.5 mg, E2006 5.0 mg, E2006 10.0 mg, E2006 25.0 mg, E2006 50.0 mg, E2006 100 mg, E2006 200 mg, Zolpidem 10 mg, E2006 Matched Placebo or Zolpidem Matched Placebo, E2006 Matched Placebo | Insomnia | 122 | 2012-08-11actual | — | 2020-01-18 |
| Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy SubjectsNCT01511783Incidence of adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: E2609, Placebo | Healthy | 50 | Jul 2012actual | — | 2015-11-03 |
| Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.NCT02268812results2018-10-25observationalAverage Overall Change From Baseline (Visit 1) in Visual Analog Scale of Pain Intensity (VASPI) | — | Completed | — | Pain Management, Severe Chronic Pain | 219 | Jul 2012actual | — | 2018-10-25 |
| A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)NCT02421042Pharmacokinetics of lenvatinib: CmaxOpen-label · Treatment | Phase 1 | Completed | Drug: Lenvatinib | Hepatic Impairment, Hepatic Function | 14 | Jul 2012actual | — | 2015-05-05 |
| E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue SarcomaNCT00413192results2017-03-22Progression Free Survival (PFS) at 12 WeeksOpen-label · Treatment | Phase 2 | Completed | Drug: E7389 | Soft Tissue Sarcoma | 128 | Jun 2012actual | — | 2017-04-26 |
| A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501NCT01549054Change in plasma concentrations of drug for each dose over time as measured by AUC, CMAX, TMaxRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: 10-mg dose of E5501 2G tablet, 10-mg dose of E5501 cyclodextrin oral solution, 10-mg dose of E5501-P21% powder, 10-mg dose of E5501 lipid-based oral | Idiopathic Thrombocytopenic Purpura | 28 | Jun 2012actual | — | 2013-11-01 |
| A Study of MORAb-009 in Patients With Solid TumorNCT01018784To investigate dose-limiting toxicity and estimate maximum tolerated dose.Open-label · Treatment | Phase 1 | Completed | Drug: MORAb-009 | Cancer, Mesothelin-positive | 17 | May 2012actual | — | 2016-01-21 |
| Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease ProgressionNCT01111461results2016-04-18Objective Response Rate (ORR)Open-label · Treatment | Phase 2 | Completed | Drug: Lenvatinib | Endometrial Cancer | 133 | May 2012actual | — | 2023-06-22 |
| A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type DementiaNCT01276353results2014-08-01Maximum Observed Plasma Concentration (Cmax) of E2020 on Visits 2 and 3Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: E2020, E2020 | Alzheimer's Type Dementia | 45 | Apr 2012actual | — | 2014-08-08 |
| A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)NCT00619099results2013-09-18The Overall Improvement RateRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: decitabine, decitabine | Myelodysplastic Syndrome | 67 | Mar 2012actual | — | 2013-10-24 |
| A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast CancerNCT01268150results2016-08-09Objective Response Rate (ORR)Open-label · Treatment | Phase 2 | Completed | Drug: Eribulin mesylate | Locally Recurrent, Metastatic Breast Cancer ( HER2 Negative) | 56 | Mar 2012actual | — | 2023-06-22 |
| Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.NCT01437384Plasma concentrations of E5501Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E5501 | Idiopathic Thrombocytopenic Purpura (ITP) | 36 | Mar 2012actual | — | 2012-05-21 |
| E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and TaxanesNCT00337103results2013-09-30Overall Survival (OS)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Eribulin Mesylate, Capecitabine | Metastatic Breast Cancer | 1,276 | 2012-03-12actual | — | 2020-06-18 |
| E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125NCT01133756results2016-12-05Number of Participants With Dose Limiting Toxicity (DLT)Randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: poor accrual | Drug: Lenvatinib, Carboplatin, Gemcitabine | Ovarian Cancer | 7 | Feb 2012actual | — | 2023-06-22 |
| A Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Extension Study)NCT01136954results2013-02-06Treatment Emergent Non-Serious Adverse Events With Greater Than 5% FrequencyOpen-label · Treatment | Phase 3 | Completed | Drug: Zonisamide | Partial Seizures | 144 | Jan 2012actual | — | 2016-01-25 |
| A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy VolunteersNCT02199392Pharmacokinetics of lenvatinib: CmaxOpen-label · Treatment | Phase 1 | Completed | Drug: Lenvatinib | P-glycoprotein, Healthy Volunteers | 15 | Jan 2012actual | — | 2015-02-16 |
| A Study of E7080 in Subjects With Solid TumorNCT01268293results2015-03-06Number of Participants With Dose Limiting Toxicity (DLT)Open-label · Treatment | Phase 1 | Completed | Drug: E7080 | Cancer | 9 | Dec 2011actual | — | 2023-06-22 |
| A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid TumorsNCT00268905results2013-01-25Maximum Tolerated Dose (MTD) of Eribulin Mesylate of E7389 in Combination With Carboplatin in Subjects With Advanced Solid Tumors.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E7389 + carboplatin AUC 5, E7389 + carboplatin AUC 6, E7389+carboplatin AUC 6 | Cancer | 64 | Nov 2011actual | — | 2013-02-12 |
| E7080 Food Effect Study in Healthy SubjectsNCT01240408To determine the effect of food on the bioavailability of lenvatinib.Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: HOPE, HOPE | Cancer | 16 | Nov 2011actual | — | 2015-03-04 |
| E2022 Patch Formulation Multiple Dose StudyNCT01450839Composite (or Profile) of PharmacokineticsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: E2022, Placebo | Healthy | 16 | Nov 2011actual | — | 2012-06-01 |
| Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic ProceduresNCT00914927results2018-01-23Percentage of Participants Experiencing ResponseRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Avatrombopag, Avatrombopag, Placebo | Thrombocytopenia Related to Chronic Liver Disease | 130 | 2011-11-11actual | — | 2018-01-23 |
| A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy SubjectsNCT01221259To evaluate the safety and tolerability of single ascending oral doses of E2212 in healthy subjects.Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: E2212, placebo | Alzheimer's Disease | 60 | Oct 2011actual | — | 2013-05-22 |
| A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy SubjectsNCT01221818Evaluate the safety and tolerability of single oral ascending doses of E6007 in healthy subjectsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: E6007, E6007, E6007, E6007, E6007, E6007 | Inflammatory Bowel Disease | 48 | Oct 2011actual | — | 2014-07-11 |
| Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly CohortNCT01294540Safety and tolerability as evidenced by the number of subjects with adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Drug: E2609, Placebo | Alzheimer's Disease | 73 | Oct 2011actual | — | 2013-08-29 |
| Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese SubjectsNCT01390714Pharmacodynamic effect by ph monitoring will be evaluated.Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E3710, E3710 | Gastroesophageal Reflux Disease | 30 | Oct 2011actual | — | 2012-03-14 |
| A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic MelanomaNCT00121680To determine the maximum tolerated dose (MTD) of E7080 for two different schedules incorporating dose interruptions.Open-label · Treatment | Phase 1 | Completed | Drug: E7080 | Metastatic Melanoma | 115 | Sep 2011actual | — | 2015-12-11 |
| Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)NCT00941109Pharmacokinetic (PK) endpoints will be decitabine PK parameters: Tmax, Cmax, AUC0-inf, t1/2 and F.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: decitabine, decitabine, decitabine, decitabine | Myelodysplastic Syndrome | 12 | Sep 2011actual | — | 2023-06-18 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to MethotrexateNCT00965757results2015-06-19Percentage of American College of Rheumatology [ACR] 20 Criteria RespondersRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: T-614, Placebo | Rheumatoid Arthritis | 253 | 2011-09-30actual | — | 2021-12-17 |
| A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult MalesNCT01506752PK Parameter Cmax, calculated from plasma E2020 concentration by a non-compartmental analysis, will be evaluated.Randomized · Open-label | Phase 1 | Completed | Drug: Donepezil Hydrochloride, Donepezil Hydrochloride, Donepezil Hydrochloride, Donepezil Hydrochloride | Healthy Adult | 20 | Sep 2011actual | — | 2012-06-27 |
| A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) SubjectsNCT00943553Primary Endpoint (Core Component): Complete Remission (CR) Rate as defined by International Working Group - 2003 criteriaRandomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Terminated by Sponsor | Drug: decitabine Induction Chemotherapy, Induction Chemotherapy | Acute Myelogenous Leukemia (AML) | 0 | Aug 2011actual | — | 2015-04-13 |
| A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)NCT01089543results2013-11-19Rate of Complete Dyspepsia Symptom ReliefRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Rabeprazole, Rabeprazole, Rabeprazole, Placebo | Functional Dyspepsia | 338 | Aug 2011actual | — | 2013-12-24 |
| Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed TherapiesNCT01142661results2013-09-20SafetyNon-randomized · Open-label · Treatment | Not applicable | Completed | Drug: Eribulin Mesylate | Breast Cancer | 9 | Aug 2011actual | — | 2013-09-20 |
| A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)NCT01146951results2013-11-21Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Rufinamide (E2080), Placebo | Lennox-Gastaut Syndrome | 66 | Aug 2011actual | — | 2018-01-24 |
| Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 ActivityNCT01241669To evaluate the effects of multiple doses of E5555 on single dose pharmacokinetics of metformin.Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: E5555, E5555 | Healthy Subjects | 104 | Aug 2011actual | — | 2014-07-11 |
| A Study to Characterize Pharmacokinetics (PK) and Pharmacodynamics (PD) of LUSEDRA® Administered as Continuous Infusion or Bolus Compared With Continuous Infusion of Propofol Injectable EmulsionNCT01308541Arterial plasma levels of fospropofol and propofol during each treatment:Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: arm 1, LUSEDRA, Propofol (arm 3) | Monitored Anesthesia Care | 20 | Aug 2011actual | — | 2015-11-03 |
| A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc IntervalNCT01525394To evaluate the potential for QT/QTc prolongation by 32 mg lenvatinib using a placebo control and moxifloxacin as the positive control.Randomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: Lenvatinib, Moxifloxacin 400 mg, Placebos (matched to 4 mg and 10 mg lenvatinib capsules). | Refractory Solid Tumors, Lymphomas | 52 | Aug 2011actual | — | 2023-06-22 |
| A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid TumorsNCT00794781Maximum tolerated dose and dose-limiting toxicities as determined in Part A.Open-label · Treatment | Phase 1 | Completed | Drug: E6201 | Advanced Solid Tumors | 55 | 2011-08-01actual | — | 2022-10-14 |
| E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)NCT00832819results2015-03-06Maximum Tolerated Dose (MTD)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E7080, E7080, Paclitaxel, Carboplatin | Non-small-cell Lung Cancer | 28 | Jul 2011actual | — | 2015-04-30 |
| Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial SeizuresNCT00848549results2013-01-15Percentage of Participants Remaining in the Study at Each VisitRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Zonisamide, Carbamazepine | Epilepsy | 295 | Jun 2011actual | — | 2015-12-24 |
| A Study of E7050 Administered Orally to Patients With Advanced Solid TumorsNCT00921869Determination of the MTD of E7050 given orally twice daily. MTD is the highest dose at which no more than 1 out of 6 patients experiences dose-limiting toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E7050 | Solid Tumors | 16 | Jun 2011actual | — | 2017-12-26 |
| A Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special PopulationsNCT01127438results2013-02-08Number of Participants With Sedation SuccessRandomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: fospropofol disodium Subgroup 1 Lower Dose, fospropofol disodium Subgroup 1 Approved Dose, fospropofol disodium Subgroup 2 Lower Dose, fospropofol disodium Subgroup 2 Approved Dose, fospropofol disodium Subgroup 3 Lower Dose, fospropofol disodium Subgroup 3 Approved Dose | Sedation | 153 | Jun 2011actual | — | 2013-02-08 |
| A Clinical Trial to Study the Effects of a Fixed Dose Combination of Diclofenac and Eperisone Hydrochloride With Plain Eperisone Hydrochloride in Patients With Low Back PainNCT01300312Finger to Floor Distance: Improvement in Finger to Floor Distance compared to baseline.Randomized · Single-masked · Treatment | Phase 3 | Completed | Drug: Eperisone hydrochloride and Diclofenac sodium, Eperisone hydrochloride | Acute Musculoskeletal Spasm Due to Low Back Pain | 239 | Jun 2011actual | — | 2013-01-08 |
| Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic DrugNCT01630057Number of Participants with Adverse Events as a Measure of Safety and Tolerability in patients who respond to zonisamide added as third drug after failure of a two-drug combination therapyRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Adjunctive Zonisamide, Replacement with Zonisamide | Partial Seizures | 200 | Jun 2011actual | — | 2014-07-14 |
| A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy VolunteersNCT02198170Pharmacokinetics of CYP3A4 and p-glycoprotein inhibition on lenvatinib: CmaxRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: ketoconazole-placebo, placebo-ketoconazole | Healthy Volunteers | 18 | Jun 2011actual | — | 2015-02-13 |
| A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid TumorsNCT00908908results2012-01-27Excretion Balance of Radio-labeled 14C-eribulin: Total Recovery of Radioactive Dose in Urine and Feces.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: eribulin | Advanced Solid Tumors | 6 | May 2011actual | — | 2012-03-09 |
| Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109)NCT01192113Value of the Peripheral Neuropathy Total Symptom Score (TSS) Compared to BaselineRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Mecobalamin IV Injection, Mecobalamin IM injection, Mecobalamin IV or IM injection | Peripheral Neuropathy | 1,072 | May 2011actual | — | 2012-11-07 |
| An Study of Efficacy and Safety of ClevudineNCT01192854Value of log10 hepatitis B virus (HBV) DNA decreases form baseline.Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Clevudine, Adefovir | Chronic Hepatitis B | 288 | May 2011actual | — | 2013-05-14 |
| A Bioequivalence Study of Film-coated Tablet and Dry Syrup 1% Form for E2020 in Healthy Japanese Adult MalesNCT01506739PK Parameter Cmax, calculated from plasma E2020 concentration by a non-compartmental analysis, will be evaluated.Randomized · Open-label | Phase 1 | Completed | Drug: Donepezil Hydrochloride, Donepezil Hydrochloride, Donepezil Hydrochloride | Healthy Adult | 12 | May 2011actual | — | 2012-01-10 |
| Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy SubjectsNCT01327872Area under the plasma concentration-time course profile (AUC) and maximum observed plasma concentration (Cmax) under fasted and fed conditionsRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: E5501 40 mg 2 x 20-mg tablets, orally, fasted, E5501 40 mg 2 x 20-mg tablets, orally, with food, E5501 40mg 2 x 20-mg tablets, orally, fasted, E5501 40 mg 2 x 20-mg tablets, orally, with food | Purpura, Thrombocytopenic, Idiopathic, Acute Idiopathic Thrombocytopenic Purpura, Chronic Thrombocytopenia | 84 | Apr 2011actual | — | 2012-03-09 |
| A Study in Healthy Subjects to Determine the Effects When Alcohol is Administered With PerampanelNCT01531920Part A: Changes on Psychomotor Performance (Continuous Tracking Test [CTT]), due to perampanel and alcohol combined and perampanel aloneRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: alcohol + placebo, alcohol + perampanel, perampanel + alcohol, placebo + alcohol | Central Nervous System | 59 | Apr 2011actual | — | 2012-02-13 |
| Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by HistologyNCT00784303results2019-08-01Objective Response Rate (ORR)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Lenvatinib (DTC Cohort), Lenvatinib (MTC Cohort) | Thyroid Cancer | 117 | 2011-04-11actual | — | 2020-04-22 |
| Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung CancerNCT01104155results2017-02-14Objective Response Rate (ORR)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: eribulin mesylate + erlotinib, eribulin mesylate + erlotinib | Non-small Cell Lung Cancer | 123 | 2011-04-07actual | — | 2023-06-22 |
| Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)NCT00566254results2012-12-11Percentage of Participants With a Decrease From Baseline in 28-day Seizure Frequency of =50%(Responder) in the Maintenance Period(LOCF)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Zonisamide, Placebo | Epilepsy; Paediatric Partial Onset Seizures | 207 | Mar 2011actual | — | 2013-05-13 |
| A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy BodiesNCT00598650results2014-09-03Change From Baseline in Mini-mental State Examination (MMSE) TotalNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: E2020 | Dementia With Lewy Bodies (DLB) | 160 | Mar 2011actual | — | 2014-09-03 |
| E2022 Patch Formulation Single Dose Phase I StudyNCT01253434Comparison of pharmacokinetics of E2022 patch (type A, B, C, D, E) with single dose of E2020 5 mg tablets.Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E2022, E2022, E2022, E2022, E2022 | Japanese Healthy Male Adult Volunteers | 80 | Mar 2011actual | — | 2013-05-14 |
| A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy SubjectsNCT01289509• To evaluate the bioavailability (BA) , as measured by AUC point estimates of E5501 40 mg tablet Lot P01010ZZA (test) relative to E5501 40 mg tablet Lot P97001ZZB (reference).Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E5501, Drug: E5501 | Idiopathic Thrombocytopenia Purpura | 42 | Mar 2011actual | — | 2013-11-01 |
| Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy SubjectsNCT01396577Cmax of 6 x 2-mg perampanel tablets (reference) compared to that of the 12-mg perampanel tablet (test),Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: perampanel, perampanel | Healthy | 54 | Mar 2011actual | — | 2012-05-04 |
| Demonstrate Bioequivalence Between 6 ? 2-mg Tablets of Perampanel and a Single 12-mg Tablet of Perampanel in Healthy SubjectsNCT01396590Cmax of 6 x 2-mg perampanel tablets (reference) compared to that of the 12-mg perampanel tablet (test)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Perampanel, Perampanel | Healthy | 54 | Mar 2011actual | — | 2012-05-04 |
| A PK/PD Study of Fospropofol Disodium Compared With Propofol Injectable EmulsionNCT01260142results2017-01-27Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Fospropofol (AUC(0-inf))Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Fospropofol disodium, propofol, Fospropofol disodium, propofol, Fospropofol disodium, propofol | Anesthesia | 36 | Feb 2011actual | — | 2017-01-27 |
| A Clinical Study in Healthy Male Volunteers to Compare the Bioequivalence of Fixed Dose Combination of Eperisone Hydrochloride 50mg Plus Diclofenac Sodium 50mg as Capsule With Eperisone Hydrochloride 50mg and Diclofenac Sodium 50mg Tablets Under Fasting Conditions (Study 013-10)NCT01306318Oral bioavailabilities: Maximum Concentration (Cmax) of eperisone and diclofenac fixed dose capsules versus eperisone & diclofenac tabletsRandomized · Open-label · Treatment | Not applicable | Completed | Drug: eperisone hydrochloride plus diclofenac sodium capsule, eperisone hydrochloride tablet and diclofenac sodium tablet | Healthy Volunteers | 24 | Feb 2011actual | — | 2015-11-17 |
| To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid TumorsNCT03002493Best overall tumor responseOpen-label · Treatment | Phase 1 | Completed | Drug: Eribulin mesylate, Eribulin mesylate, Rifampicin | Tumor | 14 | Feb 2011actual | — | 2017-03-15 |
| Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid TumorsNCT01127178results2024-10-10Maximum Tolerated Dose (MTD) for E7016 in Combination With TemozolomideOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic decision, which is unrelated to safety | Drug: E7016 + TMZ | Solid Tumors | 12 | 2011-02-24actual | — | 2024-10-10 |
| FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal CancerNCT01133990results2023-11-07Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs)Randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: The study was terminated early as the combination of E7820 and FOLFIRI was deemed to be not tolerable, hence no efficacy analysis was conducted. | Drug: FOLFIRI, E7820, Bevacizumab | Colorectal Cancer | 5 | 2011-02-18actual | — | 2023-11-07 |
| ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe SepsisNCT00334828All-cause mortality at Day 28.Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: eritoran tetrasodium, Placebo | Severe Sepsis | 2,000 | Jan 2011actual | — | 2017-07-25 |
| To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.NCT01011283results2013-09-18Overall Response Rate (ORR), Defined as Proportion of Patients Having Complete Response (CR) and Marrow Complete Response (mCR) After Completion of 3 Cycles of Study Drug.Randomized · Open-label · Treatment | Phase 4 | Terminatedsponsor's stated reason: The study was stopped due to insufficient enrollment. | Drug: decitabine, azacitidine | Myelodysplastic Syndromes | 26 | Jan 2011actual | — | 2014-10-29 |
| Single and Multiple Dose Asian Bridging StudyNCT01251731• To compare the single-dose pharmacokinetics (PK), as measured by AUCinf of three doses of E5501 (10, 40, and 80 mg) in healthy Japanese and Chinese subjects relative to healthy Caucasian subjectsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: E5501, E5501, E5501, E5501 | Healthy Subjects | 36 | Jan 2011actual | — | 2012-04-06 |
| A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial EpilepsyNCT00477295results2013-02-08Percentage of Participants Who Experienced Seizure Freedom for 26-weeks During the Maintenance PhaseRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Zonisamide, Carbamazepine | Epilepsy | 583 | Dec 2010actual | — | 2015-12-24 |
| To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial SeizuresNCT00699582results2012-11-22Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: E2007 (perampanel), E2007 (perampanel), Placebo | Refractory Partial Seizures | 389 | Dec 2010actual | — | 2014-07-11 |
| Study of E7389 for Advanced or Metastatic Breast CancerNCT00965523results2013-08-15Number of Subjects With Adverse Events.Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Eribulin Mesylate | Breast Cancer | 81 | Dec 2010actual | — | 2013-08-15 |
| A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)NCT01202071results2012-11-27Percentage Duration With An Intragastric pH >= 4 During The Entire 24 Hours Of Day 5 AdministrationRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: Rabeprazole sodium, 5 mg Tablets, Rabeprazole sodium, 10 mg Tablets, Rabeprazole sodium, 20 mg Tablets, Rabeprazole sodium, 40 mg Tablets (two 20 mg Tablets) | Healthy | 24 | Dec 2010actual | — | 2012-11-30 |
| A Study to Evaluate the Effects of Diltiazem, a Moderate CYP3A4/A5 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of E5555 and Its Metabolites in Healthy SubjectsNCT01261156Evaluate the effects of diltiazem on the pharmacokinetics (PK ie. Cmax, Tmax, AUC and half-life) of E5555 and its known metabolites.Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E5555 100 mg and diltiazem, E5555 300 mg and diltiazem | Healthy Subjects | 24 | Dec 2010actual | — | 2014-07-11 |
| Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy VolunteersNCT02533102E7050 pharmacokinetic parameter: tmax (time to maximum plasma concentration)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E7050 | Healthy Subjects | 42 | Dec 2010actual | — | 2015-11-20 |
| A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis VulgarisNCT01268527results2021-06-11Summary Statistics and Primary Pairwise Comparison (Vehicle-E6201) of Area Under the Curve (AUC) for the Baseline-Corrected Thickness of the Psoriatic InfiltrateRandomized · Treatment | Phase 2 | Completed | Drug: 0.03% E6201, 0.1% E6201, 0.2% E6201, 0.005% E6201, 0.01% E6201, 0.05% E6201, Calcipotriene · Other: Placebo - 0.03% gel vehicle, Placebo - 0.1% gel vehicle, Placebo - 0.2% gel vehicle, Placebo - 0.05% gel vehicle, Placebo - 0.01% gel vehicle, Placebo - 0.05% gel vehicle | Psoriasis Vulgaris | 30 | 2010-12-11actual | — | 2021-06-11 |
| A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)NCT01054456results2020-12-23Percentage of Participants With Complete Response (CR) During Acute Period (0 to 24 Hours) After Receiving Treatment on Day 1Open-label · Prevention | Phase 2 | Completed | Drug: palonesetron | Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC | 36 | 2010-12-08actual | — | 2020-12-23 |
| Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain CancerNCT00525590results2020-03-16Rate of Deterioration in Neurocognitive Functioning (NF) at Month 12Open-label · Treatment | Phase 2 | Completed | Drug: GLIADEL | Metastatic Brain Cancer | 69 | 2010-12-01actual | — | 2020-03-16 |
| A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial SeizuresNCT01546688results2013-02-06Change From Baseline in CVST of the FePsy Test (Mean Reaction Time) by Visit During Titration and Maintenance PeriodRandomized · Quadruple-masked · Treatment | Phase 4 | Terminated | Drug: Zonisamide at targeted daily doses of 100-500 mg/day, Placebo administered to match targeted daily doses of 100-500 mg/day | Epilepsy | 41 | Nov 2010actual | — | 2016-01-08 |
| A Study to Investigate the Potential Pharmacokinetic Interaction of Perampanel With Oral Contraceptives in Healthy Female SubjectsNCT01209858Part A: Pharmacokinetics (PK) of ethinylestradiol (EE) and levonorgestrel (LN)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Perampanel and Microgynon-30, Perampanel and Microgynon-30 | Partial Onset Epilepsy | 48 | Oct 2010actual | — | 2013-05-17 |
| Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial SeizuresNCT00699972results2013-02-05Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: E2007 (perampanel), E2007 (perampanel), Placebo | Refractory Partial Seizures | 390 | 2010-10-19actual | — | 2020-01-10 |
| QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid TumorsNCT01106248results2012-04-13Mean Time-matched, Baseline Corrected QTcF at Any Time Point Postdosing.Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Eribulin Mesylate | Advanced Solid Tumor | 26 | Sep 2010actual | — | 2012-04-13 |
| A Study to Demonstrate Bioequivalence Between 6 x 2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy SubjectsNCT01240187To evaluate and compare the pharmacokinetic (PK) profile, safety, and tolerability of 6 x 2-mg tablets of perampanel with a single 12-mg tablet.Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: perampanel, perampanel | Partial Onset Epilepsy | 22 | Sep 2010actual | — | 2013-05-14 |
| A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg TabletsNCT01153659Percentage of time that intragastric pH remains >4Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E3810, Aciphex (rabeprazole), Nexium (esomeprazole) | Healthy | 90 | Aug 2010actual | — | 2013-11-01 |
| BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes MellitusNCT00603291results2013-02-07Co-primary Endpoint- Percentage of Participants Achieving Greater Than or Equal to 5% Weight Loss From Baseline to Week 52Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo | Obesity | 604 | Jun 2010actual | — | 2019-10-02 |
| A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy SubjectsNCT01260155To determine the bioavailability (BA) of E5501 in one 40 mg new tablet formulation relative to two 20 mg old tablet formulation.Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E5501, E5501, E5501 | Healthy Subjects | 16 | Jun 2010actual | — | 2013-11-01 |
| A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.NCT02578316results2017-06-20Maximum Plasma Concentration (Cmax) of Radiolabeled 14^C-Lenvatinib and Non-Radiolabeled LenvatinibOpen-label · Treatment | Phase 1 | Completed | Drug: Lenvatinib | Advanced Solid Tumors, Lymphomas | 6 | Jun 2010actual | — | 2017-06-20 |
| A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)NCT00770510results2013-02-04Latency To Persistent Sleep (LPS)Randomized · Double-masked · Treatment | Phase 2/3 | Completed | Drug: Eszopiclone 1 mg, Eszopiclone 2 mg, Eszopiclone 3 mg, Placebo, Zolpidem Tartrate 10 mg | Primary Insomnia | 192 | May 2010actual | — | 2013-02-04 |
| A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)NCT00770692results2012-11-22Incidence of Adverse EventsRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Eszopiclone 1 mg- Elderly, Eszopiclone 2 mg- Elderly, Eszopiclone 3 mg- Non-elderly, Eszopiclone 2 mg- Non-elderly | Insomnia | 369 | May 2010actual | — | 2012-11-22 |
| Study of E3810 for Healthy Japanese Male (Under Fasting Condition)NCT01085695The following pharmacokinetic parameters are calculated: maximum drug concentration (Cmax) in plasma; area under the plasma concentration time curve (AUC)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: rabeprazole, rabeprazole, rabeprazole, rabeprazole | Healthy | 16 | May 2010actual | — | 2013-05-13 |
| A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Postprandial Condition)NCT01085708The following pharmacokinetic parameters are calculated: maximum drug concentration (Cmax) in plasma; area under the plasma concentration time curve (AUC)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: rabeprazole, rabeprazole, rabeprazole, rabeprazole | Healthy | 16 | May 2010actual | — | 2013-05-13 |
| Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial SeizuresNCT00448539results2012-12-10Percentage Change in Total Partial Seizure Frequency Per 28 Days Relative to the Baseline PhaseNon-randomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: The study was terminated early by the sponsor due to the discontinuation of clinical development for rufinamide. | Drug: Rufinamide | Refractory Partial Onset Seizures | 286 | 2010-05-14actual | — | 2019-11-22 |
| Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's DiseaseNCT00566501results2012-06-19Number of Participants With Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Donepezil | Alzheimer's Disease | 915 | 2010-04-01actual | — | 2021-11-17 |
| Pharmacokinetics Study of Donepezil HCl in Subjects Receiving Haemodialysis.NCT01063556Pharmacokinetics parameter: maximum drug concentration in plasmaRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: donepezil HCl, donepezil HCl | End-Stage Renal Disease | 6 | Mar 2010actual | — | 2013-05-14 |
| A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)NCT00543855results2013-02-18Cognitive Function: Change From Baseline in Mini-mental State Examination (MMSE) Total at Week 12 Last Observation Carried Forward (LOCF)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: 3 mg Donepezil hydrochloride, 5 mg Donepezil hydrochloride, 10 mg Donepezil hydrochloride, Placebo | Dementia With Lewy Bodies (DLB) | 167 | Feb 2010actual | — | 2013-03-08 |
| A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)NCT01055834results2013-02-12Pharmacokinetic Parameter (Bioequivalence): Maximal Drug Concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Eszopiclone 3 mg, Eszopiclone 1 mg | Insomnia | 42 | Feb 2010actual | — | 2013-02-12 |
| Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)NCT00967499results2021-01-11Percentage of Participants With Complete ControlRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: Ondansetron, Palonosetron | Postoperative Nausea and Vomiting | 239 | 2009-12-18actual | — | 2021-01-11 |
| A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid TumorsNCT00309179Objective tumor response (CR or PR) and disease control (CR, PR or SD) rates will be evaluated in this study based on RECIST criteria and modified WHO criteria.Open-label · Treatment | Phase 2 | Completed | Drug: E7820 plus cetuximab | Advanced Colorectal Cancer | 41 | 2009-12-14actual | — | 2017-09-14 |
| Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)NCT00592904results2013-02-08Mean Change From Baseline in Short Form-McGill Pain Questionnaire (SF-MPQ): Sensory and Affective Scores, From Baseline to Week 48.Open-label · Treatment | Phase 2/3 | Completed | Drug: E2007 | Neuralgia | 262 | Nov 2009actual | — | 2016-01-21 |
| Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux EsophagitisNCT00770913results2012-04-13Percentage of Participants With Healing Demonstrated Via Upper Gastrointestinal Endoscopy (Modified Los Angeles Classification: Grade N)Randomized · Double-masked · Treatment | Phase 2/3 | Completed | Drug: E3810, E3810, E3810 | Refractory Reflux Esophagitis | 337 | Nov 2009actual | — | 2012-04-18 |
| An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)NCT00849212results2013-02-07Maximum Tolerated Dose (MTD)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: E2007 | Refractory Partial Seizures | 30 | Nov 2009actual | — | 2013-02-07 |
| An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid MalignanciesNCT00121732Determine the maximum tolerated dose of E7974 in patients with solid malignancies.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E7974, E7974 | Solid Tumor Malignancies, Cancer | 39 | Oct 2009actual | — | 2015-07-01 |
| Trial of Decitabine in Patients With Acute Myeloid LeukemiaNCT00260832results2011-09-21Overall Survival in Patients 65 Years or Older Who Have Newly Diagnosed de Novo or Secondary AML.Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Cytarabine or Supportive Care, Dacogen (decitabine) only | Acute Myeloid Leukemia | 485 | Oct 2009actual | — | 2019-09-11 |
| Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular DementiaNCT00165763Clinician's Interview Based Impression of Change-Plus Caregiver Input (CIBIC-Plus).Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: donepezil hydrochloride (Aricept) | Vascular Dementia | 36 | Sep 2009actual | — | 2012-05-04 |
| A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary SyndromeNCT00619164Safety and tolerability: Adverse events, bleeding events, clinical laboratory tests, Coagulation tests, vital signs and 12-lead ECG.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: E5555, E5555, E5555, Placebo | Acute Coronary Syndrome | 240 | Sep 2009actual | — | 2013-05-13 |
| Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)NCT00658528results2015-06-23Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 WeeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Rabeprazole sodium, Esomeprazole | Gastroesophageal Reflux Disease (GERD) | 1,061 | Sep 2009actual | — | 2015-12-21 |
| Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)NCT00658775results2015-06-23Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 WeeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Rabeprazole sodium, Esomeprazole | Gastroesophageal Reflux Disease (GERD) | 1,069 | Sep 2009actual | — | 2015-12-21 |
| ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic DrugsNCT00659958Frequency of seizures.Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Zonisamide | Epilepsy | 32 | Sep 2009actual | — | 2013-05-13 |
| Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh SystemNCT00706095results2012-01-30Mean (SD) Pharmacokinetic (PK) Parameter Area Under Concentration Time Curve From Zero to Infinity (AUC0-oo)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E7389, E7389, E7389 | Cancer | 18 | Sep 2009actual | — | 2012-03-27 |
| To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food IntakeNCT00829140To assess the effect of lorcaserin on 24h energy metabolism (measured in a respiratory chamber) after 56 days of treatment.Randomized · Double-masked | Phase 1 | Completed | Drug: Placebo, Lorcaserin 10mg BID | Obesity | 56 | Sep 2009actual | — | 2019-09-12 |
| A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid MalignanciesNCT00130169Determine the maximum tolerated dose of E7974 in patients with solid malignancies.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E7974 | Cancer, Malignant Tumors | 30 | Aug 2009actual | — | 2015-07-01 |
| A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized SeizuresNCT00292461results2011-08-15The Percentage Change of Monthly Seizure Frequency at the End of the 16-week Treatment From BaselineRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Zonisamide, Lamotrigine | Epilepsy | 64 | Aug 2009actual | — | 2013-05-20 |
| Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial SeizuresNCT00700310results2012-11-22Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: perampanel, perampanel, perampanel, Placebo | Refractory Partial Seizures | 712 | Aug 2009actual | — | 2016-01-21 |
| Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)NCT00839306results2015-11-16Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Rabeprazole ER, Ranitidine | Gastroesophageal Reflux Disease (GERD) | 240 | Aug 2009actual | — | 2016-02-08 |
| Evaluating the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid TumorsNCT01000376results2013-09-23Mean (SD) Maximum Observed Concentration (Cmax) of EribulinNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Eribulin alone, Eribulin plus Ketoconazole | Cancer | 12 | Aug 2009actual | — | 2013-09-23 |
| BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity ManagementNCT00603902results2013-02-07Co-primary Endpoint- Percentage of Participants Achieving Greater Than or Equal to 5% Weight Loss From Baseline to Week 52Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo | Obesity | 4,008 | Jul 2009actual | — | 2019-10-04 |
| Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)NCT00838526results2015-06-23Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Rabeprazole ER, Ranitidine | Gastroesophageal Reflux Disease (GERD) | 240 | 2009-07-31actual | — | 2022-04-25 |
| Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)NCT00911534results2016-02-02Mean Percentage of Diary-Recorded Heartburn-Free Days at Week 4Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: rabeprazole sodium, Placebo | Symptomatic Gastroesophageal Reflux Disease (sGERD) | 305 | Jul 2009actual | — | 2016-02-02 |
| A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid TumoursNCT00459823To determine MTD of E7107. Safety and tolerability.Non-randomized · Open-label · Treatment | Phase 1 | Suspended | Drug: E7107 | Cancer | 40 | Jun 2009 | — | 2009-03-24 |
| Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's DiseaseNCT00478205results2013-02-05Change From Baseline to Week 24 in SIB Total ScoreRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Aricept (donepezil SR 23 mg), Aricept (donepezil IR 10 mg) | Alzheimer's Disease | 1,467 | Jun 2009actual | — | 2014-07-11 |
| A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid TumorsNCT00499499Tumor assessments should be performed at screening and then every 2 cycles. A best response according to RECIST (Response Evaluation Criteria in Solid Tumors) will be documented by the investigator for each patient.Non-randomized · Open-label · Treatment | Phase 1 | Suspended | Drug: E7107 | Cancer | 40 | Jun 2009 | — | 2009-02-04 |
| Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003NCT00625443results2018-03-16Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Blinded (placebo), Open Label (Avatrombopag tablets), Blinded (Avatrombopoag tablets) | Idiopathic Thrombocytopenic Purpura | 53 | Jun 2009actual | — | 2018-03-16 |
| Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's DiseaseNCT00711204CSDD (Cornell Scale for Depression in Dementia).Randomized · Double-masked · Treatment | Phase 4 | Withdrawnsponsor's stated reason: No patients were enrolled in the study. | Drug: Donepezil Hydrochloride (Aricept) | Severe Alzheimer's Disease | 0 | Jun 2009actual | — | 2012-12-10 |
| An Open Label Dose Escalation Study Of E7080NCT00121719results2016-05-27Maximum Tolerated Dose (MTD)Open-label · Treatment | Phase 1 | Completed | Drug: Lenvatinib | Solid Tumor or Lymphoma | 82 | 2009-06-19actual | — | 2023-06-22 |
| A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine CervixNCT00264732Cervical intraepithelial neoplasia (CIN) 2/3 resolution, defined as the histological evaluation of cervical tissue (presence or absence of CIN 2/3 as determined by pathology consensus diagnosis) at the End of Observation (EOO) period.Randomized · Triple-masked · Treatment | Phase 2/3 | Completed | Drug: Amolimogene, Amolimogene · Other: Placebo | Uterine Cervical Dysplasia | 251 | May 2009actual | — | 2013-05-29 |
| E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast CancerNCT00388726results2012-01-30Overall SurvivalRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: E7389, Physician's Choice | Breast Cancer | 762 | May 2009actual | — | 2020-01-07 |
| Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer TreatmentNCT00688376results2020-03-27Change From Baseline in the Test of Variables in Attention-Continuous Performance Test (TOVA-CPT) "D-prime" Standard Score (SS) at Week 12Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Donepezil hydrochloride, Placebo | Attention Impairment | 72 | 2009-05-26actual | — | 2022-01-05 |
| Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial SeizuresNCT00334958results2013-02-05Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline PhaseRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Placebo, Rufinamide | Epilepsy | 356 | 2009-05-20actual | — | 2021-06-14 |
| Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary SyndromeNCT00548587Safety and tolerabilityRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: E5555, Placebo | Acute Coronary Syndrome | 600 | Apr 2009actual | — | 2016-02-04 |
| Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)NCT00658632results2015-06-23Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 WeeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Rabeprazole sodium, Esomeprazole | Gastroesophageal Reflux Disease (GERD) | 1,397 | Apr 2009actual | — | 2016-05-04 |
| Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug UsersNCT00828659To evaluate the abuse potential of lorcaserinRandomized · Double-masked · Other | Phase 1 | Completed | Drug: Placebo, Active Comparator #1, Active Comparator #2, Active Comparator #3, Lorcaserin Dose #1, Lorcaserin Dose #2, Lorcaserin Dose #3 | Drug Abuse, Healthy | 35 | Apr 2009actual | — | 2019-09-12 |
| A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery DiseaseNCT00540670Safety and tolerability: Adverse events, bleeding events, clinical laboratory tests, Coagulation tests, vital signs and 12-lead ECGRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: E5555 50 mg, E5555 100 mg, E5555 200 mg, Placebo | Coronary Artery Disease | 240 | Mar 2009actual | — | 2013-05-13 |
| BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity ManagementNCT00395135results2013-02-07Year 1: Co-Primary Endpoint- Proportion (%) of Patients Achieving > or = 5% Weight Loss From Baseline to Week 52Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Lorcaserin 10 mg BID, Matching Placebo BID | Obesity | 3,182 | Feb 2009actual | — | 2019-10-02 |
| Pharmacokinetic Properties of Lorcaserin in Subjects With Renal ImpairmentNCT00828438The primary objective of this study is to assess the pharmacokinetic properties of lorcaserin in subjects with mild, moderate or severe renal impairment as compared to subjects with normal renal function.Open-label · Other | Phase 1 | Completed | Drug: Lorcaserin 10mg | Renal Impairment | 40 | Feb 2009actual | — | 2019-09-12 |
| Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)NCT00441090results2018-01-04Responder Rate (RR) to Avatrombopag on Day 28Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Placebo, Avatrombopag tablets | Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic | 64 | Jan 2009actual | — | 2018-03-07 |
| The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living FacilityNCT00571064results2018-03-12Mini Mental State Examination (MMSE) Total Scores by VisitOpen-label · Treatment | Phase 4 | Completed | Drug: Donepezil HCl | Mild to Severe Alzheimer's Disease | 97 | Dec 2008actual | — | 2018-09-27 |
| Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)NCT00592774results2013-02-15Change From Baseline in Average Pain Scores to Week 15/ End of Treatment (EOT) (Including Modified BOCF Data)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: E2007 (perampanel), Placebo | Neuralgia | 146 | Dec 2008actual | — | 2013-02-15 |
| Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium ValproateNCT00713622Percent change from Baseline in 28-day seizure frequency at Week 12; response rate at 12 weeks.Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Zonisamide, Sodium valproate | Epilepsy | 2 | Dec 2008actual | — | 2015-11-03 |
| Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly SubjectsNCT00828581To compare the single-dose pharmacokinetic (PK) parameters of lorcaserin in the obese or overweight Elderly (> 65) to those obtained from the obese or overweight Adult (18-65)Open-label · Other | Phase 1 | Completed | Drug: lorcaserin | Obesity | 24 | Dec 2008actual | — | 2023-06-18 |
| Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted StateNCT00828724To evaluate the pharmacokinetic properties of a single oral dose of lorcaserin in the fed versus fasted stateOpen-label · Other | Phase 1 | Completed | Drug: Lorcaserin 10mg | Obesity | 24 | Dec 2008actual | — | 2019-09-12 |
| Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic ImpairmentNCT00828932The primary objective of this study is to evaluate the pharmacokinetic properties of lorcaserin in subjects with mild or moderate hepatic impairment compared to subjects with normal hepatic function.Open-label · Other | Phase 1 | Completed | Drug: Lorcaserin | Hepatic Impairment | 24 | Dec 2008actual | — | 2019-09-12 |
| Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECTNCT00566462results2012-12-24Change in Striatal [^123I]-Iodobenzamine (IBZM_ Binding Following a Single Dose Carbidopa/Levodopa Challenge for 15-hours at Baseline and Week 4Randomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Study stopped due to lack of efficacy. | Drug: perampanel, placebo | Parkinson's Disease | 1 | 2008-12-01actual | — | 2018-09-06 |
| Adjunctive Zonisamide in Primary Generalised Tonic Clonic SeizuresNCT00692003results2012-10-12Number of Participants Considered Responders as Assessed During the Maintenance PeriodRandomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Sponsor's decision | Drug: Zonisamide, Placebo | Epilepsy | 21 | Nov 2008actual | — | 2017-03-14 |
| Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised EpilepsyNCT00693017results2012-09-12Number of Participants Considered Responders as Assessed During the Maintenance PeriodRandomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Sponsor's decision | Drug: Zonisamide, Placebo | Epilepsy | 10 | Nov 2008actual | — | 2015-12-24 |
| Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17NCT00754052results2018-04-23Mean Change From Baseline in Vineland-II Adaptive Behavior Scale (VABS-II) Parent/Caregiver Rating Form (PCRF) Score Using Last Observation Carried Forward (LOCF)Randomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Sufficient evidence of efficacy not met. Discontinuation not based on any safety concerns. | Drug: Aricept (donepezil hydrochloride), Aricept (donepezil hydrochloride), Placebo | Down Syndrome, Cognitive Dysfunction | 8 | Nov 2008actual | — | 2018-04-23 |
| A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related DonorsNCT00756912Safety and assessments will be done daily.Non-randomized · Open-label · Prevention | Phase 1 | Terminatedsponsor's stated reason: This study was terminated in November 2008 due to "a business decision (resources)". | Drug: E5564 | Leukemia | 30 | Nov 2008actual | — | 2014-07-11 |
| Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled TrialNCT00675025results2021-03-29Change From Visit 1 (Baseline) to Visit 4 or Early Termination in the Vineland Adaptive Behavior Scales, 2nd Edition, Parent/Caregiver Rating Form (VABS-II/PCRF) Sum of the 9 Sub-domain V-scoresOpen-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sufficient evidence of efficacy not met. Discontinuation not based on any safety concerns. | Drug: Donepezil hydrochloride (Aricept) | Down Syndrome | 117 | 2008-11-13actual | — | 2021-03-29 |
| A Clinical Trial of Decitabine in Patients With Myelodysplastic SyndromeNCT00282399Phase I: To determine which of the subcutaneous (SQ) doses of decitabine administered twice daily for 5 days maximizes genomic demethylation in patients with MDS.Randomized · Open-label · Treatment | Phase 1 | Terminated | Drug: Subcutaneous Decitabine | Myelodysplastic Syndrome | 41 | Oct 2008actual | — | 2015-10-28 |
| A Study of ZYC300 Administered With Cyclophosphamide Pre-DosingNCT00381173Determine the feasibility, safety and tolerability of administering ZYC300 intramuscularly every other wk for 6 doses (400 micrograms DNA/total dose) to the study pop. pre-dosed with 600 mg/m^2 cyclophosphamide intravenously 3 days prior to study drug.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing) | Breast Cancer, Ovarian Cancer, Prostate Cancer, Colon Cancer, Renal Cancer | 22 | Oct 2008actual | — | 2013-05-14 |
| Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10NCT00754013results2013-02-13Vineland-II Adaptive Behavior Scales (VABS-II) Parent/Caregiver Rating Form (PCRF) Sum of the 9 Sub-domain V-scores (3 Scores for Each of the Communication, Daily Living Skills, and Socialization Domains) Using Last Observation Carried Forward.Randomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Sufficient evidence of efficacy not met. | Drug: Aricept (Donepezil hydrochloride), Placebo | Down Syndrome, Cognitive Dysfunction | 9 | Oct 2008actual | — | 2020-01-28 |
| Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential HypertensionNCT00130156Blood PressureRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Bunazosin, Doxazosin, Valsartin | High Blood Pressure | 93 | Sep 2008actual | — | 2013-05-14 |
| An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid TumorsNCT00280397results2015-03-06Maximum Tolerable Dose (MTD) of E7080 Repeatedly Administered Twice a DayOpen-label · Treatment | Phase 1 | Completed | Drug: E7080 | Cancer: Solid Tumors | 27 | Sep 2008actual | — | 2016-10-07 |
| Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down SyndromeNCT00570128results2021-04-19Mean Change From Baseline in V-Scale Composite Score (Sum of 9 Sub-Domains) of Vineland Adaptive Behavior Scales Second Edition-Parent Caregiver Rating Form (VABS-II/PCRF) at Week 10-Last Observation Carried Forward (LOCF)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Donepezil HCl, Placebo | Down Syndrome | 129 | 2008-09-05actual | — | 2021-04-19 |
| A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell LymphomaNCT00211185results2020-03-18Summary of All Adverse Events by Frequency in Greater Than 20% of Treated ParticipantsOpen-label · Treatment | Phase 2 | Completed | Drug: Denileukin diftitox, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone · Other: Pegfilgrastim | Lymphoma, T-Cell, Peripheral | 49 | Aug 2008actual | — | 2020-03-18 |
| Neural Correlates In Mild Alzheimer's DiseaseNCT00477659results2021-11-10Percent Change From Baseline to Week 12 Based on Hippocampus Connectivity Index (HCI)Open-label · Treatment | Phase 4 | Completed | Drug: Donepezil hydrochloride | Alzheimer's Disease | 14 | 2008-08-15actual | — | 2021-11-10 |
| An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic NeuropathyNCT00505284results2013-02-08Change in Average Pain Scores From Baseline to Week 15/End of Treatment (EOT)Randomized · Double-masked · Treatment | Phase 2/3 | Completed | Drug: Placebo, E2007 (2 mg), E2007 (4 mg), E2007 (6 mg), E2007 (8 mg) | Diabetic Neuropathy | 352 | Jul 2008actual | — | 2014-07-11 |
| Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet ChemotherapyNCT00100932results2012-01-31Overall Objective Response Rate (ORR)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: E7389 28 Day Cycle, E7389 21 Day Cycle | Non-Small-Cell Lung Carcinoma | 106 | Jun 2008actual | — | 2012-03-27 |
| A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic SyndromesNCT00260065results2009-09-04Number of Participants Who Achieved Overall ResponseNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Decitabine | Myelodysplastic Syndrome | 99 | Jun 2008actual | — | 2013-05-20 |
| Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type PsoriasisNCT00539929Total Symptom Severity (TSS) at week 8.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: E6201 0.005%, E6201 0.01%, E6201 0.03%, Placebo | Chronic Plaque Psoriasis | 100 | Jun 2008actual | — | 2017-02-06 |
| Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor FluctuationsNCT01634360results2013-02-05Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension StudyOpen-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Due to termination of clinical program for Parkinson's Disease | Drug: Perampanel | Parkinson's Disease | 185 | Jun 2008actual | — | 2014-07-09 |
| Evaluating the Efficacy and Safety of Zonisamide in the Treatment of Partial SeizuresNCT00327717results2014-08-15Median Percent Change From Baseline in All Partial Seizure Frequency (Complex Partial Seizures (CP)+ Simple Partial Seizures (SP) + Secondary Generalization Seizures (SGS)) During the Fixed-dose PhaseRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Zonisamide, Placebo | Partial Seizures | 240 | May 2008actual | — | 2014-08-15 |
| Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsNCT00360308results2012-11-22Mean Change From Baseline in Total Daily OFF Time (Hours) to Week 18 (Including LOCF Data)Randomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Study stopped due to lack of efficacy. | Drug: Placebo, E2007, E2007 | Parkinson's Disease | 723 | Apr 2008actual | — | 2014-07-11 |
| A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsNCT00360412results2013-02-05Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension StudyNon-randomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: Study stopped due to lack of efficacy. | Drug: E2007 | Parkinson's Disease | 997 | Apr 2008actual | — | 2014-07-11 |
| A Study of E2007 In Patients With Parkinson's DiseaseNCT00427011results2013-02-05Mean Change From Baseline by Visit in Absolute OFF Time (Hours) During Open-label Extension StudyNon-randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Study stopped due to lack of efficacy. | Drug: E2007 | Parkinson's Disease | 25 | Apr 2008actual | — | 2013-02-11 |
| Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor FluctuationsNCT00505622results2012-11-22Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension StudyOpen-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: Study stopped due to lack of efficacy. | Drug: Perampanel | Parkinson's Disease | 328 | Apr 2008actual | — | 2016-01-21 |
| Post-marketing Study of Monteplase ("Cleactor") in Patients With Acute Pulmonary EmbolismNCT00442234Monteplase antigen levels in plasma; Monteplase activity in plasma; parameters of coagulating and fibrinolytic system (Plasminogen activity, a2-PI, PIC, fibrinogen, D-dimer).Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Monteplase | Pulmonary Embolism | 5 | 2008-04-01actual | — | 2018-10-18 |
| Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery DiseaseNCT00312052Safety and tolerability - especially the risk of bleedingRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: E5555, Placebo | Coronary Artery Disease | 720 | Mar 2008actual | — | 2016-12-05 |
| Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological MarkersNCT00403520Evolution of the volume of the Hippocampi, measured by magnetic resonance imaging (MRI), between D0 and final visit (12 months ).Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Experimental 1, Placebo Comparator | Alzheimer's Disease | 240 | Mar 2008actual | — | 2014-07-14 |
| Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)NCT00358644results2009-09-07Complete Response = Morphologic Complete Remission (mCR)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Decitabine | Acute Myeloid Leukemia | 55 | Feb 2008actual | — | 2013-05-20 |
| Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial SeizuresNCT00416195results2012-11-22Percentage of Responders During the Maintenance PhaseRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: E2007, Placebo | Epilepsy | 48 | Feb 2008actual | — | 2014-07-11 |
| Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior ChemotherapyNCT00278993results2012-05-15Objective Prostate Specific Antigen (PSA) Response Rate Based on Bubley CriteriaNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: E7389 | Prostate Cancer | 108 | Jan 2008actual | — | 2014-07-14 |
| Phase I Clinical Study of E7389NCT00326950results2011-12-20Number of Subjects Who Experienced Dose Limiting Toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E7389 | Cancer | 15 | Jan 2008actual | — | 2012-03-08 |
| Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsNCT00368108results2013-02-05Mean Change From Baseline in Total Daily OFF Time (Hours) to Week 20 (Including Last Observation Carried Forward [LOCF] Data)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: 2 mg perampanel, 4 mg perampanel, placebo comparator | Parkinson's Disease | 752 | Jan 2008actual | — | 2013-05-20 |
| A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid TumorsNCT00165802Determine the maximum tolerated dose of E7974 in patients with Advanced Solid Tumors.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E7974 | Cancer, Malignant Tumors | 40 | Dec 2007actual | — | 2013-05-22 |
| Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.NCT00306735Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Palonosetron | Multiple Myeloma | 75 | Dec 2007actual | — | 2016-12-05 |
| A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and CapecitabineNCT00246090results2012-05-15Objective Response RateNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: E7389 | Breast Cancer | 298 | Sep 2007actual | — | 2014-07-14 |
| A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive ImpairmentNCT00934375results2009-07-08Number of Participants With Treatment-Emergent Adverse EventsRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Aricept (donepezil hydrochloride), placebo | Mild Cognitive Impairment | 145 | Sep 2007actual | — | 2014-01-14 |
| Open Label, Zonegran (Zonisamide) In Partial Onset SeizuresNCT00215592Seizure frequency, compared to baseline.Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Zonegran | Epilepsy | 1,000 | Jul 2007actual | — | 2016-01-08 |
| The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsNCT00286897Patient diaries: Change from baseline to final efficacy visit in the mean total daily OFF time (hr).Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: E2007 | Parkinson's Disease | 702 | Jun 2007actual | — | 2015-11-03 |
| EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)NCT00230568FOME (Fuld Object Memory Evaluation); SDMT (Symbol Digit Modalities Test); NPI (Neuropsychiatric Inventory); MMSE (the Mini-Mental State Examination).Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Aricept | Alzheimer's Disease | 100 | Apr 2007actual | — | 2011-04-01 |
| Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid TumorsNCT00374660Confirmed response rate: Hepatocellular Cancer (HCC) Cohort: Response Evaluation Criteria in Solid Tumors (RECIST) criteria.Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: Oxaliplatin, Irofulven | Liver Cancer | 63 | Apr 2007actual | — | 2021-12-08 |
| A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole SodiumNCT00125736Ratio of S2-stage transition at 8 weeks after the study administration.Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: E0671, rabeprazole sodium, E0671 placebo | Stomach Ulcer | 520 | 2007-04-19actual | — | 2018-10-29 |
| A Comparative Study of KES524 in Patients With Obesity DiseaseNCT00165685Change and percent change in body weightRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Sibutramine Hydrochloride Monohydrate | Obesity | — | Mar 2007actual | — | 2010-01-29 |
| The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)NCT00293176Assessment of cognitive and global function in subjects with MCI.Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Donepezil Hydrochloride, Placebo | Memory Loss | 821 | Mar 2007actual | — | 2011-04-01 |
| E2007 Given as Adjunctive Therapy in Patients With Refractory Partial SeizuresNCT00144690To determine the maximum tolerated dose (MTD) of E2007 given bid or qd in patients with refractory partial-onset seizures (including secondarily generalized seizures)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: E2007 (perampanel), Placebo | Epilepsy | — | Feb 2007actual | — | 2015-11-03 |
| Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis WomenNCT00165698results2011-08-11Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 MonthsRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: menatetranone, alfacalcidol | Postmenopausal Osteoporosis | 240 | Jan 2007actual | — | 2014-07-22 |
| A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's LymphomaNCT00211276Disease Response will be evaluated by CT or MRI scans at baseline, every 8 weeks while on therapy, and every 3 months after therapy, using standard response criteria defined by Cheson et al.Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: ONTAK (denileukin diftitox) | Lymphoma, B-Cell | 50 | Jan 2007actual | — | 2012-03-14 |
| A Study of E7389 in Advanced/Metastatic Breast Cancer PatientsNCT00097721results2013-03-15Overall Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST)Open-label · Treatment | Phase 2 | Completed | Drug: E7389 | Breast Neoplasms | 104 | Nov 2006actual | — | 2013-04-22 |
| Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma PatientsNCT00051012Objective Rate of Response (ORR), defined as CR + CCR + PRNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: ONTAK | Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome | 86 | Oct 2006actual | — | 2008-03-05 |
| The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive ImpairmentNCT00103948Cognitive function.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Aricept | Cognitive Impairment | 165 | Oct 2006actual | — | 2015-11-03 |
| Study Investigating the Effect of E7337 on Tumor Like Lesions in Computed Tomography (CT) of the LiverNCT00280410Contrast enhancement effect on tumor-like lesions in the liver.Randomized · Open-label · Diagnostic | Phase 2/3 | Completed | Drug: E7337 | Lesions of the Liver | 192 | Oct 2006actual | — | 2010-01-29 |
| Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) PatientsNCT00050999Objective Rate of Response (ORR), defined as CR + CCR + PRRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: ONTAK | Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome | 195 | Sep 2006actual | — | 2008-03-05 |
| Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or LymphomaNCT00078637Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: E7820 | Neoplasms, Lymphoma, Malignant | 37 | Aug 2006actual | — | 2014-12-23 |
| Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid CancerNCT00124527To determine the objective tumor response rate in patients with anaplastic, medullary, or locally advanced/metastatic differentiated thyroid cancer treated with irofulven/capecitabine combination therapyNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Irofulven + capecitabine | Thyroid Cancer | 35 | 2006-08-31actual | — | 2021-06-16 |
| An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian SubjectsNCT00280384results2013-04-25Maximum Rates of Extensor Digitorum Brevis (EDB) Muscle M-Wave Amplitude Reduction From BaselineRandomized · Single-masked · Treatment | Phase 2 | Completed | Drug: E2014 (Botulinum toxin type B), E2014 (Botulinum toxin type B) Placebo | Spasmodic Torticollis | 48 | Aug 2006actual | — | 2013-04-25 |
| A Study of E7070 in Patients With Gastric CancerNCT00165594Phase I study:Non-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Study was completed. | Drug: E7070 | Gastric Cancer | 50 | Jul 2006actual | — | 2014-01-23 |
| Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With DementiaNCT01327859Safety and tolerability will primarily be assessed by recording of AEsNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Prior Donepezil 5mg, Prior Donzepezil 10mg, Prior Placebo | Parkinson's Disease, Dementia | 357 | Jul 2006actual | — | 2015-11-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19